{"gene":"TNFSF15","run_date":"2026-06-10T10:51:55","timeline":{"discoveries":[{"year":2002,"finding":"TL1A (TNFSF15) is a ligand for DR3 (death domain-containing receptor) and decoy receptor TR6/DcR3. TL1A binding to DR3 induces NF-κB activation and apoptosis in DR3-expressing cell lines, and TR6-Fc protein antagonizes these signaling events. In T cells, TL1A acts as a costimulator that increases IL-2 responsiveness and secretion of proinflammatory cytokines.","method":"Ligand-receptor binding assays, NF-κB reporter assays, apoptosis assays, T cell costimulation assays in vitro and in vivo","journal":"Immunity","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — direct ligand-receptor identification with multiple orthogonal functional assays (NF-κB activation, apoptosis, cytokine secretion), foundational paper replicated by many subsequent studies","pmids":["11911831"],"is_preprint":false},{"year":2003,"finding":"TL1A-DR3 interaction induces formation of a signaling complex containing TRADD, TRAF2, and RIP, and activates NF-κB and ERK, JNK, and p38 MAPK pathways. TL1A-induced NF-κB activation produces c-IAP2, which prevents DR3-mediated apoptosis in TF-1 cells. Inhibition of NF-κB or knockdown of c-IAP2 by RNA interference sensitizes cells to TL1A-induced apoptosis.","method":"Co-immunoprecipitation of signaling complex, NF-κB reporter assays, MAPK pathway inhibitors, RNA interference (siRNA knockdown of c-IAP2), apoptosis assays","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — reconstitution of signaling complex by Co-IP, multiple orthogonal methods (inhibitors, RNAi, reporter assays) in a single study","pmids":["12882979"],"is_preprint":false},{"year":1999,"finding":"TL1A (VEGI/TNFSF15) is expressed predominantly in endothelial cells, encodes a type II transmembrane protein, and the secreted (soluble) form directly inhibits endothelial cell proliferation and suppresses tumor vascularization in vivo. Local gene transfer of soluble VEGI caused complete suppression of murine colon cancer growth associated with marked reduction in vascularization.","method":"cDNA cloning from HUVEC library, gene transfer/tumor model (MC-38 murine colon cancer), in vitro endothelial cell proliferation assay, histological analysis of vascularization","journal":"FASEB journal","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — in vitro functional assay plus in vivo tumor model with histological validation, foundational paper replicated by multiple subsequent studies","pmids":["9872942"],"is_preprint":false},{"year":1999,"finding":"TL1A (TL1) induces apoptosis in endothelial cells via activation of stress-activated protein kinase (SAPK/JNK) and p38 MAPK pathways and caspase-3. TL1-induced apoptosis was reduced by dominant-interfering c-Jun mutant, p38 inhibitor SB203580, and caspase inhibitor ZVAD-fmk. The effect was not inhibited by soluble TNF receptors 1 or 2, indicating a distinct receptor.","method":"Endothelial cell apoptosis assays, kinase activity assays (SAPK, p38), dominant-negative mutant expression, pharmacological inhibitors, caspase substrate assays, immunocytochemistry","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — multiple orthogonal methods (dominant-negative, inhibitors, kinase assays) in a single study with rigorous controls","pmids":["9880523"],"is_preprint":false},{"year":1999,"finding":"VEGI (TNFSF15) activates NF-κB (inducing IκBα degradation and p65 nuclear translocation) and c-Jun N-terminal kinase in myeloid cells, inhibits proliferation of multiple tumor cell lines, and activates caspase-3 leading to PARP cleavage. Its activity cannot be neutralized by anti-TNF antibodies and it does not compete with TNF binding, indicating it acts through a distinct receptor.","method":"EMSA (NF-κB activation), reporter gene assay, IκBα degradation assay, JNK kinase assay, cell proliferation assay, caspase-3/PARP cleavage assay","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — multiple orthogonal biochemical assays (EMSA, kinase assay, reporter, PARP cleavage) in a single study","pmids":["10597252"],"is_preprint":false},{"year":2005,"finding":"VEGI-192, a new isoform of TNFSF15, systemically administered suppresses tumor growth and specifically eliminates tumor endothelial cells but not vascular smooth muscle cells, with no liver or kidney toxicity. VEGI expression in normal tissue is restricted largely to endothelial cells by immunohistochemistry.","method":"Recombinant protein production, systemic i.p./i.v./s.c. injection in Lewis lung carcinoma mouse model, histological analysis, immunohistochemistry","journal":"Clinical cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo tumor model with histological analysis of vascular cell selectivity, single lab but multiple readouts","pmids":["16061878"],"is_preprint":false},{"year":2005,"finding":"Soluble TL1A is naturally secreted from HUVECs as a 30–32 kDa protein, and its production is significantly induced by IL-1α and TNF. IL-1 is a more potent inducer than TNF, and the induction is dose- and time-dependent.","method":"ELISA development, Western blot under reducing/non-reducing conditions, affinity purification of soluble TL1A from conditioned medium","journal":"Journal of immunological methods","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct biochemical characterization (ELISA, Western blot, affinity purification) with quantitative dose-response data, single lab","pmids":["15847792"],"is_preprint":false},{"year":2007,"finding":"TL1A expression in human monocytes and monocyte-derived dendritic cells is specifically induced by FcγR signaling (immune complexes), correlating with surface and secreted TL1A protein. TLR agonists capable of inducing IL-6 and TNF-α do not induce surface or soluble TL1A. TL1A produced by monocytes enhances T cell IFN-γ responses.","method":"Stimulation assays with TLR agonists, IFN-γ, and immune complexes; surface expression by flow cytometry; TL1A ELISA; T cell co-culture assays","journal":"Journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct functional assays with defined stimuli, multiple readouts (surface expression, secretion, T cell function), single lab","pmids":["17371957"],"is_preprint":false},{"year":2008,"finding":"DR3 expression is selectively elevated in Th17 cells, and TL1A promotes proliferation of effector Th17 cells. TL1A-deficient dendritic cells have reduced capacity to support Th17 differentiation and proliferation. In experimental autoimmune encephalomyelitis (EAE), TL1A-knockout animals show decreased clinical severity and reduced Th17 differentiation and effector function.","method":"TL1A-knockout mouse generation, EAE model, flow cytometry analysis of Th17 cells, DC co-culture differentiation assays","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic KO model with defined cellular phenotype (Th17 defect), in vivo disease model, DC functional assay; independent replication of TL1A-DR3 in Th17 biology across multiple papers","pmids":["18411337"],"is_preprint":false},{"year":2009,"finding":"Crystal structure of the human TL1A extracellular domain at 2.5 Å resolution reveals a jelly-roll fold typical of the TNF superfamily. Mutagenesis and biochemical characterization define the binding interface for DcR3 and DR3 receptors, suggesting the mode of TL1A–DcR3 interaction differs from other characterized TNF ligand/receptor complexes.","method":"X-ray crystallography (2.5 Å resolution), site-directed mutagenesis, biochemical binding assays","journal":"Biochemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — crystal structure with mutagenesis and biochemical validation in a single rigorous study","pmids":["19522538"],"is_preprint":false},{"year":2009,"finding":"VEGI (TNFSF15) inhibits the differentiation of endothelial progenitor cells (EPCs) from bone marrow Sca1+ mononuclear cells, decreasing endothelial cell marker expression and capability for adhesion, migration, and capillary-like structure formation. VEGI induces apoptosis of differentiated EPCs but not early-stage EPCs; in early-stage EPCs it increases phospho-ERK and decreases phospho-Akt, while in differentiated EPCs it activates NF-κB, JNK, and caspase-3. DR3 is present only on differentiated EPCs and mediates VEGI-induced apoptosis, as shown by neutralizing anti-DR3 antibodies or recombinant DR3 extracellular domain.","method":"In vitro EPC differentiation assay, flow cytometry (EPC markers), adhesion/migration/Matrigel assays, Western blot (signaling), neutralizing antibodies against DR3","journal":"Blood","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — multiple orthogonal methods (functional assays, signaling, receptor neutralization), clearly establishes DR3 as the mediating receptor for a specific cell-stage-dependent effect","pmids":["19329781"],"is_preprint":false},{"year":2009,"finding":"Multiple bacterial species (gram-negative, gram-positive, anaerobes) induce TL1A expression in human APCs (monocytes and monocyte-derived DCs) via TLR signaling, which is inhibited by downstream blockade of p38 MAPK and NF-κB. Bacterially induced TL1A production by APCs potentiates CD4+ T-cell IFN-γ production.","method":"Bacterial stimulation assays, TL1A mRNA/protein quantification, p38 and NF-κB pathway inhibitors, T cell co-culture IFN-γ assays","journal":"European journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pathway inhibitor experiments establishing signaling requirements, multiple bacterial species tested, functional T cell readout; single lab","pmids":["19839006"],"is_preprint":false},{"year":2011,"finding":"TNFSF15 is a downstream transcriptional target of AMPK, mediated through LITAF binding to a specific sequence in the TNFSF15 promoter region. AMPK activation by AICAR upregulates TNFSF15, and this is abrogated by shRNA or dominant-negative AMPK α1. TNFSF15 inhibits growth of prostate cancer cells and bovine aortic endothelial cells in vitro, and intratumoral injection of TNFSF15 reduces tumor size and blood vessel number in vivo.","method":"shRNA knockdown, dominant-negative AMPK mutant, promoter binding assay (LITAF-TNFSF15 promoter), cell proliferation assay, xenograft tumor model, histological analysis","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple genetic and pharmacological approaches establish AMPK–LITAF–TNFSF15 regulatory axis, single lab with both in vitro and in vivo readouts","pmids":["21217782"],"is_preprint":false},{"year":2010,"finding":"Sustained TL1A expression on DCs drives goblet cell hyperplasia in the ileum associated with elevated IL-13 levels and increased IL-13- and IL-17-producing T cells. TL1A directly stimulates Treg cell proliferation in vitro and enhances Treg turnover in vivo via DR3 signaling. TL1A also attenuates the ability of Treg cells to suppress conventional T cells, requiring DR3 signaling in either conventional or Treg cells.","method":"TL1A transgenic mice (DC-specific expression), IL-13 quantification, flow cytometry of T cell subsets, in vitro Treg proliferation assay, suppression assays","journal":"Mucosal immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — transgenic mouse model with multiple cellular readouts and in vitro mechanistic validation; single lab","pmids":["20962771"],"is_preprint":false},{"year":2010,"finding":"Two functionally distinct isoforms of TL1A are generated by differential ectodomain shedding: TL1A(L72-L251) and a novel shorter fragment TL1A(V84-L251). TL1A overexpression induces premature senescence in HUVECs and endothelial progenitor cells, and knockdown of TL1A partially reverts senescence. The novel TL1A(V84-L251) fragment induces growth arrest and apoptosis in HUVECs.","method":"Ectodomain shedding characterization, TL1A overexpression and knockdown (siRNA) in HUVECs and EPCs, senescence assays, apoptosis/growth arrest assays","journal":"The journals of gerontology. Series A, Biological sciences and medical sciences","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct experimental identification of novel cleavage fragment with functional assays; single lab","pmids":["20675618"],"is_preprint":false},{"year":2013,"finding":"Soluble TL1A-Ig (a dimer of TL1A trimers) signals through TNFRSF25 to rapidly expand Foxp3+ Tregs in vivo (up to 30–35% of CD4+ T cells within 5 days), dependent on TCR engagement with MHC class II. TL1A-Ig-expanded Tregs express high levels of KLRG1 and CD103, are highly suppressive ex vivo, and protect against allergic lung inflammation in a mouse asthma model.","method":"TL1A-Ig fusion protein generation/characterization (SEC-MALS), in vivo Treg expansion assay, flow cytometry, MHC class II dependency experiments, asthma model (eosinophil/BAL analysis)","journal":"Journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — defined fusion protein with in vivo functional characterization and mechanistic (MHC dependency) validation; single lab","pmids":["23319737"],"is_preprint":false},{"year":2013,"finding":"TNFSF15 (VEGI) inhibits EPC-supported vasculogenesis by simultaneously promoting mFlt1 (membrane VEGFR1) degradation through Akt deactivation-dependent, ubiquitin-assisted degradation, and upregulating sFlt1 (soluble VEGFR1) expression via the PKC/Src/Erk1/2 signaling pathway. TNFSF15 also promotes alternative splicing of Flt1 in favor of sFlt1 by downregulating nuclear protein Jmjd6, thereby disrupting VEGF/PlGF-induced eNOS and MAPK p38 activation and inhibiting EPC-supported vasculogenesis in vivo.","method":"In vitro EPC culture, Western blot (phosphorylation, ubiquitination), pathway inhibitors (PKC, Src, Erk1/2), Jmjd6 knockdown, in vivo Matrigel implant model, alternative splicing analysis","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — multiple orthogonal biochemical and genetic approaches with in vivo validation; mechanistically detailed single study","pmids":["23918400"],"is_preprint":false},{"year":2014,"finding":"TNFSF15:DR3 interactions in human macrophages amplify PRR-initiated MAPK/NF-κB/PI3K signaling and cytokine secretion. Mechanism involves TACE-induced cleavage of TNFSF15 to soluble form, which then signals via TRADD/FADD/MALT-1 and caspase-8 to induce autocrine IL-1 secretion. The rs6478108 A disease-risk allele is associated with increased TNFSF15 expression and increased PRR-induced signaling and cytokines in macrophages.","method":"Human macrophage stimulation assays, pathway inhibitors (TACE, NF-κB, PI3K, MAPK), caspase-8 inhibition, ELISA, genotype-stratified analysis","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — multiple orthogonal mechanistic experiments (protease inhibitors, caspase-8, signaling inhibitors) plus genotype-function correlation in primary human cells","pmids":["25197060"],"is_preprint":false},{"year":2014,"finding":"TL1A directly signals through DR3 on intestinal myofibroblasts to increase collagen and IL-31Ra expression. Blocking TL1A with neutralizing antibody or deletion of DR3 reduces the number of fibroblasts and myofibroblasts and reverses established murine colonic fibrosis, reducing connective tissue growth factor, TGF-β1, and IGF-1 expression.","method":"Neutralizing anti-Tl1a antibody treatment in murine colitis model, Dr3 knockout mice, primary intestinal myofibroblast culture with TL1A stimulation, collagen and cytokine quantification","journal":"Mucosal immunology","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic (DR3 KO) and antibody blockade approaches converge on same phenotype; direct in vitro fibroblast stimulation; replicated by subsequent studies","pmids":["24850426"],"is_preprint":false},{"year":2015,"finding":"Soluble trimeric TL1A fully activates DR3-associated pro- and anti-apoptotic signaling pathways without requiring secondary oligomerization. DR3 is efficiently activated by soluble TL1A trimers (similar to TNFR1, unlike TRAIL receptors which require oligomerization). TL1A binding induces DR3 internalization, and the affinity of TL1A-DR3 interaction was measured in a cell-based system.","method":"Cell-based DR3 activation assays (apoptosis, NF-κB), comparison with oligomerized vs. non-oligomerized soluble ligand, receptor internalization assay, affinity measurement","journal":"The FEBS journal","confidence":"Medium","confidence_rationale":"Tier 1–2 / Moderate — direct mechanistic comparison of soluble vs. membrane-bound ligand activity, receptor internalization and affinity measurements; single lab","pmids":["26509650"],"is_preprint":false},{"year":2016,"finding":"TNFSF15 suppresses VEGF production in endothelial cells by stimulating miR-29b expression through activation of the JNK–GATA3 signaling pathway. miR-29b targets the 3'-UTR of VEGF transcript. Blocking TNFSF15 activity (via DR3 siRNA or neutralizing antibody 4-3H) inhibits miR-29b and reinstates VEGF production. JNK inhibitor (SP600125) or JNK siRNA eradicates TNFSF15-induced GATA3 expression; GATA3 siRNA suppresses TNFSF15-induced miR-29b.","method":"miRNA expression assay, 3'-UTR reporter assay, siRNA knockdown (DR3, JNK, GATA3), neutralizing antibody, JNK inhibitor (SP600125), qRT-PCR, Western blot","journal":"Oncotarget","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal siRNA and inhibitor approaches defining JNK-GATA3-miR-29b pathway; single lab","pmids":["27589684"],"is_preprint":false},{"year":2017,"finding":"TNFSF15 inhibits VEGF-induced vascular hyperpermeability in vitro and in vivo through DR3-mediated dephosphorylation of VEGFR2. Upon TNFSF15-DR3 interaction, SHP-1 (a phosphatase) becomes associated with DR3, and a ternary protein complex consisting of VEGFR2, DR3, and SHP-1 is formed, providing the structural basis for VEGFR2 dephosphorylation.","method":"In vitro vascular permeability assay, in vivo permeability model, Co-immunoprecipitation (VEGFR2–DR3–SHP-1 complex), Western blot (VEGFR2 phosphorylation), siRNA knockdown","journal":"FASEB journal","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — biochemical complex formation by Co-IP plus functional phosphorylation assays in vitro and in vivo; mechanistically detailed single study","pmids":["28183800"],"is_preprint":false},{"year":2018,"finding":"Membrane-bound TL1A and soluble TL1A have differential roles: membrane TL1A promotes inflammatory cytokine expression in the lung dependent on DR3 on T cells (adaptive immunity), while soluble TL1A alone is sufficient to induce intestinal type 2 inflammation independently of T cells (innate lymphoid cells). These differential activities were demonstrated using membrane-restricted TL1A-transgenic mice.","method":"Generation of membrane-restricted TL1A-transgenic mice (cleavage site mutant), comparison with soluble TL1A-expressing mice, DR3-deficient crosses, lung cytokine and intestinal pathology analysis","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic dissection using membrane-restricted transgene plus DR3-KO crosses, clearly separates membrane vs. soluble TL1A functions in defined cell populations","pmids":["29335258"],"is_preprint":false},{"year":2010,"finding":"Membrane-bound TL1A (TL1A-M) can bind DR3 through cell-cell contact and signal to induce IFN-γ secretion enhancement from IL-12/IL-18-primed CD4+ T cells. This was blocked by anti-TL1A antibody, demonstrating functional signaling capacity of the membrane-bound form.","method":"TL1A-M expression in HEK-293 cells, DR3-Fc binding assay, co-incubation with primed T cells, IFN-γ ELISA, antibody blocking","journal":"FEBS letters","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct cell-cell contact assay establishing membrane-bound TL1A functional signaling through DR3; single lab","pmids":["20403353"],"is_preprint":false},{"year":2013,"finding":"TL1A directly induces proinflammatory cytokines including TNF-α from CD3+CD161+ (CD4+CD161+) T cells. Anti-TNF-α failed to block TL1A-induced cytokine production, indicating TL1A effects are independent of and upstream of TNFα.","method":"Isolation of CD4+CD161+ T cells, TL1A stimulation, cytokine ELISA, anti-TNFα antibody blocking experiments","journal":"Mucosal immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct cell stimulation with receptor-specific blocking, establishes pathway position of TL1A upstream of TNFα; single lab","pmids":["23250276"],"is_preprint":false},{"year":2013,"finding":"Plasma cells (but not B cells) express high levels of DR3 and are direct targets of TL1A. In the presence of TL1A, plasma cells survive better and produce more anti-collagen antibody. TL1A gene knockout mice show ameliorated collagen-induced arthritis with reduced pathogenic anti-collagen Ab titers.","method":"TL1A KO mouse generation, CIA model, flow cytometry (DR3 expression on B cells and plasma cells), plasma cell survival and antibody production assays","journal":"Journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic KO model plus direct in vitro plasma cell functional assays; single lab","pmids":["24140642"],"is_preprint":false},{"year":2020,"finding":"Autocrine/paracrine TNFSF15:DR3 interactions are required for optimal PRR-induced bacterial clearance in human macrophages. TNFSF15 induces bacterial uptake via pyruvate dehydrogenase kinase 1 and promotes intracellular bacterial clearance through reactive oxygen species, nitric oxide synthase 2, and autophagy upregulation. The TNFSF15-initiated TRAF2/RIPK1/RIP3 pathway (but not the FADD/MALT-1/caspase-8 pathway) is required for MAPK and NF-κB activation and antimicrobial pathways.","method":"Human monocyte-derived macrophage assays, flow cytometry, ELISA, gentamicin protection assay (bacterial clearance), pathway inhibitors (TRAF2, RIPK1, RIP3, FADD, caspase-8), ROS/NOS2/autophagy assays, genotype-stratified analysis of IBD risk carriers","journal":"Cellular and molecular gastroenterology and hepatology","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple pathway inhibitors and complementation experiments defining mechanistic pathway in primary human cells; genotype-function correlation adds further rigor","pmids":["32827707"],"is_preprint":false},{"year":2020,"finding":"TL1A directly signals through DR3 on lung fibroblasts and bronchial epithelial cells to induce proliferation and production of fibrotic molecules (collagen, periostin), driving airway remodeling. Neutralization of TL1A or genetic deletion of DR3 restricts peribronchial smooth muscle mass and lung collagen accumulation in allergen- and bleomycin-driven mouse models. Recombinant TL1A administered into naive mouse airways drives remodeling independently of innate lymphoid cells and adaptive immunity.","method":"Anti-TL1A antibody neutralization, DR3-KO mice, recombinant TL1A instillation in naive mice, human lung fibroblast and bronchial epithelial cell culture with TL1A stimulation, collagen/periostin quantification","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic (DR3 KO) and antibody approaches converge; direct structural cell stimulation experiments; in vivo cell-type independent model establishes direct fibroblast mechanism","pmids":["32958689"],"is_preprint":false},{"year":2020,"finding":"Direct TL1A-DR3 signaling on fibroblasts promotes intestinal fibrosis in vivo. Transfer of TL1A-overexpressing T cells into Rag-/- mice with DR3 deleted specifically on fibroblasts (Rag-/-Dr3ΔCol1a2) showed reduced intestinal fibrosis and attenuated fibroblast activation and migration compared to Rag-/- controls, despite similar inflammation. RNA-Seq of TL1A-stimulated fibroblasts identified Rho signal transduction as a major activated pathway, and inhibition of this pathway modulated TL1A-mediated fibroblast functions.","method":"Adoptive T cell transfer into Rag-/-, Rag-/-Dr3-/-, and Rag-/-Dr3ΔCol1a2 mice, collagen deposition quantification, RNA-Seq of TL1A-stimulated fibroblasts, Rho pathway inhibition","journal":"Scientific reports","confidence":"High","confidence_rationale":"Tier 2 / Strong — cell-type-specific DR3 KO (fibroblast-selective) definitively establishes direct TL1A-fibroblast signaling in vivo; RNA-Seq identifies downstream pathway; single rigorous study","pmids":["33097818"],"is_preprint":false},{"year":2014,"finding":"DR3 mediates TNFSF15-induced endothelial cell apoptosis. siRNA-mediated knockdown of DR3 confers resistance to TNFSF15-induced apoptosis. DR3-depleted cells show increased ERK1/2 MAPK activity and upregulation of anti-apoptotic proteins c-FLIP and Bcl-2. Additionally, TNFα-induced apoptosis is also dependent on TNFSF15 upregulation stimulated by TNFα, as TNFSF15 siRNA or neutralizing antibody inhibits TNFα-induced apoptosis.","method":"siRNA knockdown of DR3 and TNFSF15, in vivo Matrigel angiogenesis assay, endothelial cell culture apoptosis assays, Western blot (ERK, c-FLIP, Bcl-2), neutralizing antibody (4-3H)","journal":"The international journal of biochemistry & cell biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple siRNA and antibody experiments in vitro and in vivo Matrigel assay; single lab","pmids":["25161149"],"is_preprint":false},{"year":2024,"finding":"TL1A is constitutively expressed as an epithelial alarmin in alveolar epithelium at steady state in mice and humans (including airway basal cells). Upon synergistic activation by IL-33 and TL1A, lung ILC2s acquire a transient IL-9highGATA3low 'ILC9' phenotype and produce large amounts of IL-9. Large-scale proteomic analysis, lung intravital microscopy, and adoptive transfer experiments revealed that IL-9high distinguishes a multicytokine-producing ILC2 state with increased capacity to initiate IL-5-dependent allergic airway inflammation.","method":"Proteomic analyses, lung intravital microscopy, adoptive transfer of ILC9 cells, in vitro ILC2 stimulation (IL-33 + TL1A), flow cytometry, IL-9/IL-5 functional assays in mouse models","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods (proteomics, live imaging, adoptive transfer, in vitro stimulation); identifies new cellular mechanism and cell source of TL1A","pmids":["38597952"],"is_preprint":false},{"year":2018,"finding":"The IBD-risk haplotype at TNFSF15 is associated with decreased expression of TNFSF15 by peripheral blood monocytes (at both RNA and protein levels) under various stimulation conditions, maintained after macrophage differentiation. The regulatory polymorphism controlling TNFSF15 expression was localized to the upstream regulatory region of the gene using recall-by-genotype fine-mapping. Genetically regulated TNFSF15 has functional relevance as shown by a T cell costimulation assay.","method":"Recall-by-genotype functional fine-mapping, allele-specific expression measurement, monocyte stimulation assays (RNA and protein), macrophage differentiation, T cell costimulation assay","journal":"PLoS genetics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — allele-specific expression fine-mapping with functional validation; defines regulatory mechanism of disease-associated variant; single study","pmids":["30199539"],"is_preprint":false},{"year":2009,"finding":"TL1A gene haplotype B increases TL1A expression in response to FcγR stimulation in Jewish CD patients positive for OmpC antibody. CD14+ monocytes from patients homozygous for haplotype B express higher levels of TL1A, and peripheral monocytes show increased membrane TL1A expression.","method":"SNP haplotyping, monocyte isolation and FcγR stimulation, ELISA for TL1A protein, flow cytometry for membrane TL1A","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — haplotype-stratified functional assay in primary human monocytes; single lab","pmids":["19262684"],"is_preprint":false},{"year":2018,"finding":"TL1A-mediated intestinal fibrosis and fibroblast activation are dependent on specific microbial populations. In germ-free Tl1a-transgenic mice, the pro-fibrotic and inflammatory phenotype is abrogated. Reconstitution with SPF (but not healthy human) microbiota restores intestinal collagen deposition and fibroblast activation. Candidate organisms correlating with fibrosis were identified and shown to directly impact fibroblast function in vitro.","method":"Germ-free Tl1a-transgenic mice, microbiome reconstitution by gavage (SPF vs. human donor stool), collagen deposition quantification, fibroblast migration/activation assays in vitro","journal":"Mucosal immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — germ-free genetic model with microbiome reconstitution and in vitro fibroblast functional assays; single lab","pmids":["29988118"],"is_preprint":false},{"year":2021,"finding":"TL1A promotes EMT (epithelial-mesenchymal transition) in intestinal epithelial cells via the TGF-β1/Smad3 pathway, with increased expression of IL-13 and EMT transcription factors ZEB1 and Snail1. TL1A-induced EMT is inhibited by anti-TL1A antibody or BMP-7 in vitro.","method":"IBD patient tissue analysis, TL1A transgenic mouse DSS-colitis model, HT-29 cell stimulation with TL1A/anti-TL1A/BMP-7, Western blot and qPCR for EMT markers (E-cadherin, FSP1, α-SMA), pathway analysis (TGF-β1/Smad3)","journal":"Mediators of inflammation","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vitro and in vivo models with antibody blockade establishing TGF-β1/Smad3 pathway involvement; single lab","pmids":["34257516"],"is_preprint":false},{"year":2018,"finding":"TL1A mediates RA fibroblast-like synoviocyte (FLS) migration and activates Indian Hedgehog (IHH) signaling, including upregulation of IHH and its receptors PTCH1 and PTCH2. This effect is mediated through TNFR2, and blocking TL1A with TNFR2 antagonist reduces IHH expression and FLS migration.","method":"RA-FLS isolation from patients, TL1A stimulation, TNFR2 antagonist blocking, qRT-PCR and Western blot (IHH, PTCH1/2), FLS migration assay","journal":"European cytokine network","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single lab, single cell type from patients, mechanistic pathway (TNFR2 mediation of IHH) based primarily on antagonist blocking without genetic validation","pmids":["29748156"],"is_preprint":false},{"year":2008,"finding":"Chicken TL1A (ChTL1A) binds to TNFR2 and decoy receptor 3 (DcR3) and decreases the viability of CHO-K1 cells transfected with chicken TNFR2 or DcR3. ChTL1A acts as a proinflammatory cytokine in chickens, and anti-ChTL1A antibody prevents LPS-induced increases in plasma nitrite/nitrate and acute phase proteins.","method":"CHO-K1 transfection with chicken TNFR2/DcR3, cell viability assay, LPS injection in vivo, acute phase protein measurement, anti-ChTL1A antibody neutralization","journal":"Journal of immunology","confidence":"Low","confidence_rationale":"Tier 3 / Weak — chicken ortholog study; receptor binding via cell viability assay (indirect), single lab, limited mechanistic depth","pmids":["18523299"],"is_preprint":false}],"current_model":"TNFSF15 (TL1A/VEGI) is a TNF superfamily type II transmembrane cytokine predominantly produced by vascular endothelial cells and APCs that exists in membrane-bound and soluble trimeric forms (generated by metalloprotease-mediated ectodomain shedding); it signals principally through its cognate receptor DR3 (TNFRSF25), recruiting a complex containing TRADD, TRAF2, and RIP to activate NF-κB, JNK, p38 MAPK, ERK, and PI3K/Akt pathways, while also signaling through caspase-8/FADD/MALT-1 for cytokine secretion and TRAF2/RIPK1/RIP3 for antimicrobial functions; on immune cells it acts as a potent T cell (Th1, Th17, Th9) costimulator and Treg expander/modulator via DR3, while on endothelial cells and progenitor cells it inhibits proliferation, induces apoptosis via caspase-3, and suppresses vasculogenesis by simultaneously degrading membrane VEGFR1 and upregulating soluble VEGFR1, and inhibiting VEGF-induced VEGFR2 phosphorylation through a DR3–SHP-1–VEGFR2 ternary complex; membrane TL1A preferentially activates adaptive T cell responses while soluble TL1A drives innate ILC2 responses; TL1A directly signals on fibroblasts via DR3-activated Rho signaling to promote intestinal and pulmonary fibrosis; and constitutive epithelial TL1A expression qualifies it as an alarmin that cooperates with IL-33 to activate ILC2s toward an IL-9-producing state."},"narrative":{"mechanistic_narrative":"TNFSF15 (TL1A/VEGI) is a TNF-superfamily type II transmembrane cytokine that operates at the interface of immune costimulation and vascular biology, signaling principally through the death-domain receptor DR3 (TNFRSF25) and being antagonized by the decoy receptor TR6/DcR3 [PMID:11911831, PMID:19522538]. Engagement of DR3 nucleates a TRADD–TRAF2–RIP signaling complex that activates NF-κB, ERK, JNK and p38 MAPK, with NF-κB-driven c-IAP2 setting the threshold between survival and apoptosis [PMID:12882979]. Soluble trimeric TL1A, generated by metalloprotease/TACE-mediated ectodomain shedding, fully activates DR3 without requiring secondary oligomerization and triggers receptor internalization [PMID:26509650, PMID:15847792, PMID:25197060]. On immune cells TL1A is a potent T cell costimulator: it increases IL-2 responsiveness and proinflammatory cytokine secretion [PMID:11911831], drives Th17 proliferation and effector function in autoimmune disease [PMID:18411337], expands and modulates Foxp3+ regulatory T cells through DR3 [PMID:20962771, PMID:23319737], and acts upstream of TNFα to elicit cytokine production from effector T cells [PMID:23250276]. In macrophages TNFSF15:DR3 amplifies pattern-recognition-receptor signaling, using a FADD/MALT-1/caspase-8 branch for autocrine IL-1 secretion and a distinct TRAF2/RIPK1/RIP3 branch to drive ROS-, NOS2- and autophagy-dependent antimicrobial clearance [PMID:25197060, PMID:32827707]. TL1A expression is induced in antigen-presenting cells by FcγR engagement, bacteria and TLR signaling, while alveolar and airway epithelium express it constitutively as an alarmin that cooperates with IL-33 to push ILC2s into an IL-9-high state initiating allergic airway inflammation [PMID:17371957, PMID:19839006, PMID:38597952]. In the vasculature TL1A inhibits endothelial cell and endothelial progenitor proliferation, induces caspase-3-dependent apoptosis, and suppresses tumor vascularization and vasculogenesis—the latter by degrading membrane VEGFR1 while upregulating soluble VEGFR1, suppressing VEGF via a JNK–GATA3–miR-29b axis, and assembling a DR3–SHP-1–VEGFR2 complex that dephosphorylates VEGFR2 [PMID:9872942, PMID:9880523, PMID:23918400, PMID:27589684, PMID:28183800]. Membrane-bound and soluble TL1A are functionally divergent—membrane TL1A drives adaptive T cell responses whereas soluble TL1A drives innate type 2 inflammation [PMID:29335258]—and direct DR3 signaling on fibroblasts via Rho signaling promotes intestinal and pulmonary fibrosis [PMID:33097818, PMID:24850426, PMID:32958689]. Disease-associated TNFSF15 haplotypes alter its expression and PRR-induced signaling, linking the gene to inflammatory bowel disease [PMID:25197060, PMID:30199539, PMID:19262684].","teleology":[{"year":1999,"claim":"Establishing that the endothelium-restricted cytokine VEGI/TL1A is an endogenous angiogenesis suppressor answered whether a TNF-family ligand could act on the vasculature itself rather than on immune cells.","evidence":"cDNA cloning from HUVEC, endothelial proliferation assays, and gene transfer in a murine colon cancer model with histological vascularization analysis","pmids":["9872942"],"confidence":"High","gaps":["Receptor not yet identified at this stage","Mechanism of growth inhibition undefined"]},{"year":1999,"claim":"Demonstrating TL1A-induced endothelial and tumor-cell apoptosis through SAPK/JNK, p38 and caspase-3, not neutralized by soluble TNF receptors or anti-TNF antibodies, established that TL1A acts via a distinct receptor from TNF.","evidence":"Endothelial/myeloid apoptosis assays, kinase assays, dominant-negative c-Jun, pharmacological inhibitors, EMSA and PARP cleavage","pmids":["9880523","10597252"],"confidence":"High","gaps":["Receptor identity unresolved","Relationship between proapoptotic and NF-κB outputs not defined"]},{"year":2002,"claim":"Identifying DR3 as the signaling receptor and TR6/DcR3 as the decoy receptor, together with T cell costimulatory activity, unified the vascular and immune activities under a single ligand-receptor system.","evidence":"Ligand-receptor binding, NF-κB reporter and apoptosis assays, and T cell costimulation assays in vitro and in vivo","pmids":["11911831"],"confidence":"High","gaps":["Downstream adaptor complex not yet mapped","Cell-type basis for apoptosis vs. costimulation outcome unclear"]},{"year":2003,"claim":"Defining the TRADD–TRAF2–RIP complex and the NF-κB/c-IAP2 survival circuit explained how DR3 partitions between proinflammatory signaling and apoptosis.","evidence":"Co-immunoprecipitation of the signaling complex, MAPK inhibitors, c-IAP2 RNAi, and apoptosis assays in TF-1 cells","pmids":["12882979"],"confidence":"High","gaps":["Stoichiometry of the complex not resolved","Cell-type determinants of the survival/death balance unaddressed"]},{"year":2005,"claim":"Characterizing soluble TL1A as a 30–32 kDa secreted product inducible by IL-1 and TNF, and an isoform (VEGI-192) with vascular-selective antitumor activity, established cytokine-regulated production and clinical anti-angiogenic potential.","evidence":"ELISA, Western blot, affinity purification from HUVEC medium; recombinant protein systemic delivery in Lewis lung carcinoma","pmids":["15847792","16061878"],"confidence":"Medium","gaps":["Protease responsible for shedding not identified here","Mechanism of vascular-cell selectivity unexplained"]},{"year":2009,"claim":"The crystal structure of the TL1A ectodomain and definition of the DR3/DcR3 binding interface provided the structural basis for receptor engagement within the TNF superfamily.","evidence":"X-ray crystallography at 2.5 Å with site-directed mutagenesis and binding assays","pmids":["19522538"],"confidence":"High","gaps":["No co-structure with DR3 or DcR3","Conformational basis for signaling not addressed"]},{"year":2009,"claim":"Showing that bacteria and FcγR/TLR signaling induce TL1A in APCs to enhance T cell IFN-γ, and that VEGI blocks endothelial progenitor differentiation via DR3, extended TL1A function into both innate-adaptive crosstalk and progenitor-cell vasculogenesis.","evidence":"Bacterial/TLR stimulation with p38 and NF-κB inhibitors and T cell co-culture; in vitro EPC differentiation with stage-dependent signaling and anti-DR3 neutralization","pmids":["19839006","19329781","17371957"],"confidence":"Medium","gaps":["Stage-specific receptor regulation not mechanistically explained","In vivo relevance of EPC effects limited"]},{"year":2008,"claim":"Genetic TL1A knockout linking DR3-high Th17 cells to autoimmune disease severity established TL1A as a driver of pathogenic effector T cell responses.","evidence":"TL1A-KO mice in EAE, flow cytometry of Th17 cells, DC co-culture differentiation assays","pmids":["18411337"],"confidence":"High","gaps":["DR3-proximal signaling in Th17 cells not dissected","Contribution of other T cell subsets not resolved here"]},{"year":2010,"claim":"Transgenic and membrane-form studies revealed TL1A both expands/modulates Tregs and signals through cell-cell contact, showing the cytokine tunes regulatory as well as effector arms of immunity.","evidence":"DC-specific TL1A transgenic mice with Treg proliferation/suppression assays; membrane TL1A expression in HEK-293 with DR3-Fc binding and T cell IFN-γ readout","pmids":["20962771","20403353"],"confidence":"Medium","gaps":["Molecular basis of Treg suppression attenuation unclear","Balance of effector vs. regulatory outcomes context-dependent"]},{"year":2011,"claim":"Identifying the AMPK–LITAF promoter axis defined a transcriptional control mechanism for TNFSF15 connecting metabolic signaling to its anti-angiogenic output.","evidence":"shRNA and dominant-negative AMPK, LITAF–promoter binding assay, proliferation assays, and xenograft model","pmids":["21217782"],"confidence":"Medium","gaps":["Physiological triggers of AMPK-driven TNFSF15 induction unclear","Generality across cell types not established"]},{"year":2013,"claim":"Dissecting ectodomain-shedding isoforms, Treg-expanding TL1A-Ig, and direct effects on plasma cells and effector T cells refined how distinct TL1A forms produce divergent immune and senescence outcomes.","evidence":"Shedding fragment characterization and senescence assays in HUVECs/EPCs; TL1A-Ig SEC-MALS and in vivo Treg expansion; plasma cell survival and CIA model; CD4+CD161+ T cell stimulation","pmids":["20675618","23319737","24140642","23250276"],"confidence":"Medium","gaps":["Protease specificities for each fragment incompletely defined","Mechanism distinguishing trimer vs. oligomer outputs not yet established"]},{"year":2014,"claim":"Mechanistic studies in macrophages, fibroblasts and endothelium established that DR3 signaling outputs branch into distinct adaptor pathways and direct stromal effects, including a definitive fibroblast-driven fibrosis mechanism.","evidence":"Macrophage signaling with TACE/caspase-8/PI3K inhibitors and genotype stratification; DR3-KO and anti-TL1A in colonic fibrosis with primary myofibroblast stimulation; DR3/TNFSF15 siRNA in endothelial apoptosis","pmids":["25197060","24850426","25161149"],"confidence":"High","gaps":["Switch determining FADD/caspase-8 vs. other branches not fully defined","Fibroblast DR3-proximal signaling not yet mapped at this stage"]},{"year":2013,"claim":"Defining the VEGFR1 axis showed TNFSF15 suppresses vasculogenesis by degrading membrane VEGFR1 and upregulating soluble VEGFR1 through Akt/PKC/Src/Erk and Jmjd6-dependent splicing.","evidence":"Endothelial progenitor culture, ubiquitination and phosphorylation Western blots, pathway inhibitors, Jmjd6 knockdown, and in vivo Matrigel model","pmids":["23918400"],"confidence":"High","gaps":["E3 ligase for membrane VEGFR1 degradation unidentified","Coordination of degradation and splicing programs unclear"]},{"year":2016,"claim":"Identifying the JNK–GATA3–miR-29b cascade and the DR3–SHP-1–VEGFR2 ternary complex established direct molecular routes by which TNFSF15 suppresses VEGF production and VEGFR2 signaling.","evidence":"miR-29b 3'-UTR reporter, DR3/JNK/GATA3 siRNA, JNK inhibitor; Co-IP of VEGFR2–DR3–SHP-1 and permeability assays in vitro and in vivo","pmids":["27589684","28183800"],"confidence":"Medium","gaps":["How DR3 recruits SHP-1 mechanistically undefined","Interplay between VEGF suppression and VEGFR2 dephosphorylation not integrated"]},{"year":2018,"claim":"Genetic separation of membrane-bound versus soluble TL1A established that the two forms drive adaptive (T cell) versus innate (ILC) inflammation respectively, resolving long-standing functional ambiguity.","evidence":"Membrane-restricted (cleavage-site mutant) TL1A transgenic mice crossed to DR3-deficient lines, with lung and intestinal pathology readouts","pmids":["29335258"],"confidence":"High","gaps":["Molecular basis for differential cellular targeting unexplained","Regulation of shedding in vivo unclear"]},{"year":2018,"claim":"Defining IBD-risk haplotype effects on TNFSF15 expression and microbiota-dependent and EMT-driven fibrosis pathways connected genetic risk, microbial signals, and stromal pathology mechanistically.","evidence":"Recall-by-genotype fine-mapping and allele-specific expression; germ-free TL1A-transgenic mice with microbiome reconstitution; TGF-β1/Smad3 EMT analysis; FcγR-stimulated monocyte haplotype assays","pmids":["30199539","29988118","34257516","19262684"],"confidence":"Medium","gaps":["Causal regulatory variant mechanism incompletely defined","Specific microbial inducers not conclusively identified"]},{"year":2020,"claim":"Defining direct DR3 signaling on fibroblasts and bronchial epithelium via Rho signaling, and macrophage antimicrobial pathways via TRAF2/RIPK1/RIP3, established TL1A as a direct driver of fibrosis and innate host defense distinct from its T cell roles.","evidence":"Fibroblast-selective DR3 deletion with adoptive T cell transfer and RNA-Seq; DR3-KO and recombinant TL1A airway models; macrophage gentamicin protection assays with TRAF2/RIPK1/RIP3 and caspase-8 inhibitors","pmids":["33097818","32958689","32827707"],"confidence":"High","gaps":["Rho effectors downstream of DR3 in fibroblasts not pinpointed","Switch between antimicrobial and proapoptotic adaptor branches not defined"]},{"year":2024,"claim":"Identifying constitutive epithelial TL1A as an alarmin cooperating with IL-33 to generate an IL-9-high ILC2 state established a tissue-resident innate mechanism for initiating allergic airway inflammation.","evidence":"Proteomics, lung intravital microscopy, adoptive transfer of ILC9 cells, and in vitro IL-33+TL1A ILC2 stimulation in mouse models","pmids":["38597952"],"confidence":"High","gaps":["Receptor/signaling integration of IL-33 and TL1A in ILC2s not resolved","Human relevance of the ILC9 state not established"]},{"year":null,"claim":"How the same DR3 engagement is routed to opposing fates—survival versus apoptosis, antimicrobial versus proapoptotic adaptor branches, and adaptive versus innate effector programs—remains the central unresolved mechanistic question.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No unified model of context-dependent DR3 output selection","Determinants of adaptor branch choice (FADD/caspase-8 vs. TRAF2/RIPK1/RIP3) undefined","No co-structure of TL1A–DR3 signaling complex"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0048018","term_label":"receptor ligand activity","supporting_discovery_ids":[0,9,19]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[0,1,21]},{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[0,1,23]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[22,23,14]},{"term_id":"GO:0005576","term_label":"extracellular region","supporting_discovery_ids":[2,6,14]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[0,1,21]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[8,13,26]},{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[1,3,10]}],"complexes":[],"partners":["TNFRSF25","TNFRSF6B","TNFRSF1B","TRADD","TRAF2","RIPK1","SHP-1","VEGFR2"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"O95150","full_name":"Tumor necrosis factor ligand superfamily member 15","aliases":["TNF ligand-related molecule 1","Vascular endothelial cell growth inhibitor"],"length_aa":251,"mass_kda":28.1,"function":"Receptor for TNFRSF25 and TNFRSF6B. Mediates activation of NF-kappa-B. Inhibits vascular endothelial growth and angiogenesis (in vitro). Promotes activation of caspases and apoptosis","subcellular_location":"Secreted","url":"https://www.uniprot.org/uniprotkb/O95150/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/TNFSF15","classification":"Not Classified","n_dependent_lines":1,"n_total_lines":1208,"dependency_fraction":0.0008278145695364238},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/TNFSF15","total_profiled":1310},"omim":[{"mim_id":"612259","title":"INFLAMMATORY BOWEL DISEASE 16; IBD16","url":"https://www.omim.org/entry/612259"},{"mim_id":"609888","title":"LEPROSY, SUSCEPTIBILITY TO, 1; LPRS1","url":"https://www.omim.org/entry/609888"},{"mim_id":"604052","title":"TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY, MEMBER 15; TNFSF15","url":"https://www.omim.org/entry/604052"},{"mim_id":"603500","title":"TUMOR NECROSIS FACTOR RECEPTOR 1-ASSOCIATED DEATH DOMAIN PROTEIN; TRADD","url":"https://www.omim.org/entry/603500"},{"mim_id":"603366","title":"TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY, MEMBER 25; TNFRSF25","url":"https://www.omim.org/entry/603366"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Nuclear membrane","reliability":"Approved"},{"location":"Nucleoplasm","reliability":"Additional"},{"location":"Cytosol","reliability":"Additional"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"intestine","ntpm":8.9}],"url":"https://www.proteinatlas.org/search/TNFSF15"},"hgnc":{"alias_symbol":["TL1","VEGI","TL1A","VEGI192A","MGC129934","MGC129935"],"prev_symbol":[]},"alphafold":{"accession":"O95150","domains":[{"cath_id":"2.60.120.40","chopping":"95-249","consensus_level":"high","plddt":92.7737,"start":95,"end":249}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/O95150","model_url":"https://alphafold.ebi.ac.uk/files/AF-O95150-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-O95150-F1-predicted_aligned_error_v6.png","plddt_mean":81.06},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=TNFSF15","jax_strain_url":"https://www.jax.org/strain/search?query=TNFSF15"},"sequence":{"accession":"O95150","fasta_url":"https://rest.uniprot.org/uniprotkb/O95150.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/O95150/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/O95150"}},"corpus_meta":[{"pmid":"11911831","id":"PMC_11911831","title":"TL1A is a TNF-like ligand for DR3 and TR6/DcR3 and functions as a T cell costimulator.","date":"2002","source":"Immunity","url":"https://pubmed.ncbi.nlm.nih.gov/11911831","citation_count":526,"is_preprint":false},{"pmid":"14568967","id":"PMC_14568967","title":"Expression, localization, and functional activity of TL1A, a novel Th1-polarizing cytokine in inflammatory bowel disease.","date":"2003","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/14568967","citation_count":258,"is_preprint":false},{"pmid":"18598698","id":"PMC_18598698","title":"TL1A (TNFSF15) regulates the development of chronic colitis by modulating both T-helper 1 and T-helper 17 activation.","date":"2008","source":"Gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/18598698","citation_count":215,"is_preprint":false},{"pmid":"18411337","id":"PMC_18411337","title":"TL1A-DR3 interaction regulates Th17 cell function and Th17-mediated autoimmune disease.","date":"2008","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/18411337","citation_count":187,"is_preprint":false},{"pmid":"9872942","id":"PMC_9872942","title":"VEGI, a novel cytokine of the tumor necrosis factor family, is an angiogenesis inhibitor that suppresses the growth of colon carcinomas in vivo.","date":"1999","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/9872942","citation_count":140,"is_preprint":false},{"pmid":"16698931","id":"PMC_16698931","title":"Role of TL1A and its receptor DR3 in two models of chronic murine ileitis.","date":"2006","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/16698931","citation_count":137,"is_preprint":false},{"pmid":"17371957","id":"PMC_17371957","title":"The T cell costimulator TL1A is induced by FcgammaR signaling in human monocytes and dendritic cells.","date":"2007","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/17371957","citation_count":130,"is_preprint":false},{"pmid":"22684480","id":"PMC_22684480","title":"Identifying and testing candidate genetic polymorphisms in the irritable bowel syndrome (IBS): association with TNFSF15 and TNFα.","date":"2012","source":"Gut","url":"https://pubmed.ncbi.nlm.nih.gov/22684480","citation_count":127,"is_preprint":false},{"pmid":"22017439","id":"PMC_22017439","title":"TL1A and DR3, a TNF family ligand-receptor pair that promotes lymphocyte costimulation, mucosal hyperplasia, and autoimmune inflammation.","date":"2011","source":"Immunological reviews","url":"https://pubmed.ncbi.nlm.nih.gov/22017439","citation_count":106,"is_preprint":false},{"pmid":"12882979","id":"PMC_12882979","title":"TL1A-induced NF-kappaB activation and c-IAP2 production prevent DR3-mediated apoptosis in TF-1 cells.","date":"2003","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12882979","citation_count":105,"is_preprint":false},{"pmid":"9880523","id":"PMC_9880523","title":"TL1, a novel tumor necrosis factor-like cytokine, induces apoptosis in endothelial cells. Involvement of activation of stress protein kinases (stress-activated protein kinase and p38 mitogen-activated protein kinase) and caspase-3-like protease.","date":"1999","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9880523","citation_count":98,"is_preprint":false},{"pmid":"21636646","id":"PMC_21636646","title":"Association of TNFSF15 polymorphism with irritable bowel syndrome.","date":"2011","source":"Gut","url":"https://pubmed.ncbi.nlm.nih.gov/21636646","citation_count":95,"is_preprint":false},{"pmid":"30972074","id":"PMC_30972074","title":"TL1A (TNFSF15) and DR3 (TNFRSF25): A Co-stimulatory System of Cytokines With Diverse Functions in Gut Mucosal Immunity.","date":"2019","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/30972074","citation_count":93,"is_preprint":false},{"pmid":"24850426","id":"PMC_24850426","title":"Inhibition of a novel fibrogenic factor Tl1a reverses established colonic fibrosis.","date":"2014","source":"Mucosal immunology","url":"https://pubmed.ncbi.nlm.nih.gov/24850426","citation_count":92,"is_preprint":false},{"pmid":"29988118","id":"PMC_29988118","title":"Inflammation-independent TL1A-mediated intestinal fibrosis is dependent on the gut microbiome.","date":"2018","source":"Mucosal immunology","url":"https://pubmed.ncbi.nlm.nih.gov/29988118","citation_count":90,"is_preprint":false},{"pmid":"21264313","id":"PMC_21264313","title":"Constitutive TL1A (TNFSF15) expression on lymphoid or myeloid cells leads to mild intestinal inflammation and fibrosis.","date":"2011","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/21264313","citation_count":89,"is_preprint":false},{"pmid":"20962771","id":"PMC_20962771","title":"Sustained TL1A expression modulates effector and regulatory T-cell responses and drives intestinal goblet cell hyperplasia.","date":"2010","source":"Mucosal immunology","url":"https://pubmed.ncbi.nlm.nih.gov/20962771","citation_count":86,"is_preprint":false},{"pmid":"34126262","id":"PMC_34126262","title":"Anti-TL1A Antibody PF-06480605 Safety and Efficacy for Ulcerative Colitis: A Phase 2a Single-Arm Study.","date":"2021","source":"Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association","url":"https://pubmed.ncbi.nlm.nih.gov/34126262","citation_count":82,"is_preprint":false},{"pmid":"17663424","id":"PMC_17663424","title":"TNFSF15 is an ethnic-specific IBD gene.","date":"2007","source":"Inflammatory bowel diseases","url":"https://pubmed.ncbi.nlm.nih.gov/17663424","citation_count":80,"is_preprint":false},{"pmid":"19262684","id":"PMC_19262684","title":"IBD-associated TL1A gene (TNFSF15) haplotypes determine increased expression of TL1A protein.","date":"2009","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/19262684","citation_count":78,"is_preprint":false},{"pmid":"26080076","id":"PMC_26080076","title":"VEGI attenuates the inflammatory injury and disruption of blood-brain barrier partly by suppressing the TLR4/NF-κB signaling pathway in experimental traumatic brain injury.","date":"2015","source":"Brain research","url":"https://pubmed.ncbi.nlm.nih.gov/26080076","citation_count":76,"is_preprint":false},{"pmid":"19839006","id":"PMC_19839006","title":"Microbial induction of inflammatory bowel disease associated gene TL1A (TNFSF15) in antigen presenting cells.","date":"2009","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/19839006","citation_count":76,"is_preprint":false},{"pmid":"23250276","id":"PMC_23250276","title":"TL1A/TNFSF15 directly induces proinflammatory cytokines, including TNFα, from CD3+CD161+ T cells to exacerbate gut inflammation.","date":"2012","source":"Mucosal immunology","url":"https://pubmed.ncbi.nlm.nih.gov/23250276","citation_count":73,"is_preprint":false},{"pmid":"15760679","id":"PMC_15760679","title":"Involvement of TL1A and DR3 in induction of pro-inflammatory cytokines and matrix metalloproteinase-9 in atherogenesis.","date":"2005","source":"Cytokine","url":"https://pubmed.ncbi.nlm.nih.gov/15760679","citation_count":71,"is_preprint":false},{"pmid":"21724600","id":"PMC_21724600","title":"Correction of the consequences of mitochondrial 3243A>G mutation in the MT-TL1 gene causing the MELAS syndrome by tRNA import into mitochondria.","date":"2011","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/21724600","citation_count":66,"is_preprint":false},{"pmid":"18287561","id":"PMC_18287561","title":"TL1A both promotes and protects from renal inflammation and injury.","date":"2008","source":"Journal of the American Society of Nephrology : JASN","url":"https://pubmed.ncbi.nlm.nih.gov/18287561","citation_count":65,"is_preprint":false},{"pmid":"21217782","id":"PMC_21217782","title":"LITAF and TNFSF15, two downstream targets of AMPK, exert inhibitory effects on tumor growth.","date":"2011","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/21217782","citation_count":65,"is_preprint":false},{"pmid":"26188076","id":"PMC_26188076","title":"The TNF-family cytokine TL1A: from lymphocyte costimulator to disease co-conspirator.","date":"2015","source":"Journal of leukocyte biology","url":"https://pubmed.ncbi.nlm.nih.gov/26188076","citation_count":63,"is_preprint":false},{"pmid":"19174806","id":"PMC_19174806","title":"TNFSF15 polymorphisms are associated with susceptibility to inflammatory bowel disease in a new European cohort.","date":"2009","source":"The American journal of gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/19174806","citation_count":62,"is_preprint":false},{"pmid":"35911746","id":"PMC_35911746","title":"Role of TL1A in Inflammatory Autoimmune Diseases: A Comprehensive Review.","date":"2022","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/35911746","citation_count":61,"is_preprint":false},{"pmid":"10597252","id":"PMC_10597252","title":"VEGI, a new member of the TNF family activates nuclear factor-kappa B and c-Jun N-terminal kinase and modulates cell growth.","date":"1999","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/10597252","citation_count":61,"is_preprint":false},{"pmid":"25197060","id":"PMC_25197060","title":"A TNFSF15 disease-risk polymorphism increases pattern-recognition receptor-induced signaling through caspase-8-induced IL-1.","date":"2014","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/25197060","citation_count":61,"is_preprint":false},{"pmid":"16061878","id":"PMC_16061878","title":"VEGI-192, a new isoform of TNFSF15, specifically eliminates tumor vascular endothelial cells and suppresses tumor growth.","date":"2005","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/16061878","citation_count":60,"is_preprint":false},{"pmid":"24453414","id":"PMC_24453414","title":"The role of TL1A and DR3 in autoimmune and inflammatory diseases.","date":"2013","source":"Mediators of inflammation","url":"https://pubmed.ncbi.nlm.nih.gov/24453414","citation_count":59,"is_preprint":false},{"pmid":"24814505","id":"PMC_24814505","title":"The TNFSF15 gene single nucleotide polymorphism rs7848647 is associated with surgical diverticulitis.","date":"2014","source":"Annals of surgery","url":"https://pubmed.ncbi.nlm.nih.gov/24814505","citation_count":59,"is_preprint":false},{"pmid":"19329781","id":"PMC_19329781","title":"Inhibition of endothelial progenitor cell differentiation by VEGI.","date":"2009","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/19329781","citation_count":56,"is_preprint":false},{"pmid":"32584596","id":"PMC_32584596","title":"The Role of the TL1A/DR3 Axis in the Activation of Group 2 Innate Lymphoid Cells in Subjects with Eosinophilic Asthma.","date":"2020","source":"American journal of respiratory and critical care medicine","url":"https://pubmed.ncbi.nlm.nih.gov/32584596","citation_count":55,"is_preprint":false},{"pmid":"24835165","id":"PMC_24835165","title":"TNFSF15 is an independent predictor for the development of Crohn's disease-related complications in Koreans.","date":"2014","source":"Journal of Crohn's & colitis","url":"https://pubmed.ncbi.nlm.nih.gov/24835165","citation_count":52,"is_preprint":false},{"pmid":"32554042","id":"PMC_32554042","title":"Common risk variants in NPHS1 and TNFSF15 are associated with childhood steroid-sensitive nephrotic syndrome.","date":"2020","source":"Kidney international","url":"https://pubmed.ncbi.nlm.nih.gov/32554042","citation_count":48,"is_preprint":false},{"pmid":"22833050","id":"PMC_22833050","title":"TNFSF15 Modulates Neovascularization and Inflammation.","date":"2012","source":"Cancer microenvironment : official journal of the International Cancer Microenvironment Society","url":"https://pubmed.ncbi.nlm.nih.gov/22833050","citation_count":47,"is_preprint":false},{"pmid":"23918400","id":"PMC_23918400","title":"TNFSF15 inhibits vasculogenesis by regulating relative levels of membrane-bound and soluble isoforms of VEGF receptor 1.","date":"2013","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/23918400","citation_count":47,"is_preprint":false},{"pmid":"6211393","id":"PMC_6211393","title":"Antitermination and termination functions of the cloned nutL, N, and tL1 modules of coliphage lambda.","date":"1981","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/6211393","citation_count":46,"is_preprint":false},{"pmid":"29436901","id":"PMC_29436901","title":"An anti-TL1A antibody for the treatment of asthma and inflammatory bowel disease.","date":"2018","source":"mAbs","url":"https://pubmed.ncbi.nlm.nih.gov/29436901","citation_count":45,"is_preprint":false},{"pmid":"26099067","id":"PMC_26099067","title":"Tumor Necrosis Factor-like Cytokine TL1A and Its Receptors DR3 and DcR3: Important New Factors in Mucosal Homeostasis and Inflammation.","date":"2015","source":"Inflammatory bowel diseases","url":"https://pubmed.ncbi.nlm.nih.gov/26099067","citation_count":45,"is_preprint":false},{"pmid":"22210436","id":"PMC_22210436","title":"Down-modulation of TNFSF15 in ovarian cancer by VEGF and MCP-1 is a pre-requisite for tumor neovascularization.","date":"2011","source":"Angiogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/22210436","citation_count":45,"is_preprint":false},{"pmid":"19918267","id":"PMC_19918267","title":"VEGI-armed oncolytic adenovirus inhibits tumor neovascularization and directly induces mitochondria-mediated cancer cell apoptosis.","date":"2009","source":"Cell research","url":"https://pubmed.ncbi.nlm.nih.gov/19918267","citation_count":44,"is_preprint":false},{"pmid":"28973304","id":"PMC_28973304","title":"Exome-wide association study reveals novel psoriasis susceptibility locus at TNFSF15 and rare protective alleles in genes contributing to type I IFN signalling.","date":"2017","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/28973304","citation_count":44,"is_preprint":false},{"pmid":"23319737","id":"PMC_23319737","title":"Cloning, expression, and functional characterization of TL1A-Ig.","date":"2013","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/23319737","citation_count":42,"is_preprint":false},{"pmid":"23638306","id":"PMC_23638306","title":"SUSTAINED TL1A (TNFSF15) EXPRESSION ON BOTH LYMPHOID AND MYELOID CELLS LEADS TO MILD SPONTANEOUS INTESTINAL INFLAMMATION AND FIBROSIS.","date":"2013","source":"European journal of microbiology & immunology","url":"https://pubmed.ncbi.nlm.nih.gov/23638306","citation_count":40,"is_preprint":false},{"pmid":"25887448","id":"PMC_25887448","title":"The TL1A/DR3/DcR3 pathway in autoimmune rheumatic diseases.","date":"2015","source":"Seminars in arthritis and rheumatism","url":"https://pubmed.ncbi.nlm.nih.gov/25887448","citation_count":39,"is_preprint":false},{"pmid":"32963108","id":"PMC_32963108","title":"TL1A inhibits atherosclerosis in apoE-deficient mice by regulating the phenotype of vascular smooth muscle cells.","date":"2020","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/32963108","citation_count":37,"is_preprint":false},{"pmid":"39266053","id":"PMC_39266053","title":"Targeting TL1A and DR3: the new frontier of anti-cytokine therapy in IBD.","date":"2025","source":"Gut","url":"https://pubmed.ncbi.nlm.nih.gov/39266053","citation_count":36,"is_preprint":false},{"pmid":"34257516","id":"PMC_34257516","title":"Effect and Mechanism of TL1A Expression on Epithelial-Mesenchymal Transition during Chronic Colitis-Related Intestinal Fibrosis.","date":"2021","source":"Mediators of inflammation","url":"https://pubmed.ncbi.nlm.nih.gov/34257516","citation_count":36,"is_preprint":false},{"pmid":"24242819","id":"PMC_24242819","title":"Immunobiology of TNFSF15 and TNFRSF25.","date":"2013","source":"Immunologic research","url":"https://pubmed.ncbi.nlm.nih.gov/24242819","citation_count":35,"is_preprint":false},{"pmid":"30199539","id":"PMC_30199539","title":"Reduced monocyte and macrophage TNFSF15/TL1A expression is associated with susceptibility to inflammatory bowel disease.","date":"2018","source":"PLoS genetics","url":"https://pubmed.ncbi.nlm.nih.gov/30199539","citation_count":35,"is_preprint":false},{"pmid":"32958689","id":"PMC_32958689","title":"TL1A Promotes Lung Tissue Fibrosis and Airway Remodeling.","date":"2020","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/32958689","citation_count":35,"is_preprint":false},{"pmid":"21188501","id":"PMC_21188501","title":"Vascular endothelial growth inhibitor (VEGI; TNFSF15) inhibits bone marrow-derived endothelial progenitor cell incorporation into Lewis lung carcinoma tumors.","date":"2010","source":"Angiogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/21188501","citation_count":34,"is_preprint":false},{"pmid":"33097818","id":"PMC_33097818","title":"Direct signaling of TL1A-DR3 on fibroblasts induces intestinal fibrosis in vivo.","date":"2020","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/33097818","citation_count":33,"is_preprint":false},{"pmid":"19522538","id":"PMC_19522538","title":"Biochemical and structural characterization of the human TL1A ectodomain.","date":"2009","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/19522538","citation_count":33,"is_preprint":false},{"pmid":"20150621","id":"PMC_20150621","title":"Expression of vascular endothelial growth inhibitor (VEGI) in human urothelial cancer of the bladder and its effects on the adhesion and migration of bladder cancer cells in vitro.","date":"2010","source":"Anticancer research","url":"https://pubmed.ncbi.nlm.nih.gov/20150621","citation_count":31,"is_preprint":false},{"pmid":"30949903","id":"PMC_30949903","title":"Effects and Mechanism of Constitutive TL1A Expression on Intestinal Mucosal Barrier in DSS-Induced Colitis.","date":"2019","source":"Digestive diseases and sciences","url":"https://pubmed.ncbi.nlm.nih.gov/30949903","citation_count":31,"is_preprint":false},{"pmid":"15847792","id":"PMC_15847792","title":"Identification of naturally secreted soluble form of TL1A, a TNF-like cytokine.","date":"2005","source":"Journal of immunological methods","url":"https://pubmed.ncbi.nlm.nih.gov/15847792","citation_count":31,"is_preprint":false},{"pmid":"38597952","id":"PMC_38597952","title":"TL1A is an epithelial alarmin that cooperates with IL-33 for initiation of allergic airway inflammation.","date":"2024","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/38597952","citation_count":30,"is_preprint":false},{"pmid":"25404161","id":"PMC_25404161","title":"TL1A regulates TCRγδ+ intraepithelial lymphocytes and gut microbial composition.","date":"2014","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/25404161","citation_count":29,"is_preprint":false},{"pmid":"27589684","id":"PMC_27589684","title":"TNFSF15 suppresses VEGF production in endothelial cells by stimulating miR-29b expression via activation of JNK-GATA3 signals.","date":"2016","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/27589684","citation_count":28,"is_preprint":false},{"pmid":"26509650","id":"PMC_26509650","title":"Soluble TL1A is sufficient for activation of death receptor 3.","date":"2015","source":"The FEBS journal","url":"https://pubmed.ncbi.nlm.nih.gov/26509650","citation_count":28,"is_preprint":false},{"pmid":"24140642","id":"PMC_24140642","title":"TNF-like ligand 1A (TL1A) gene knockout leads to ameliorated collagen-induced arthritis in mice: implication of TL1A in humoral immune responses.","date":"2013","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/24140642","citation_count":28,"is_preprint":false},{"pmid":"18523299","id":"PMC_18523299","title":"Role of chicken TL1A on inflammatory responses and partial characterization of its receptor.","date":"2008","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/18523299","citation_count":26,"is_preprint":false},{"pmid":"38574740","id":"PMC_38574740","title":"TL1A inhibition for inflammatory bowel disease treatment: From inflammation to fibrosis.","date":"2024","source":"Med (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/38574740","citation_count":24,"is_preprint":false},{"pmid":"24832108","id":"PMC_24832108","title":"TL1A increased the differentiation of peripheral Th17 in rheumatoid arthritis.","date":"2014","source":"Cytokine","url":"https://pubmed.ncbi.nlm.nih.gov/24832108","citation_count":23,"is_preprint":false},{"pmid":"20675618","id":"PMC_20675618","title":"Two functionally distinct isoforms of TL1A (TNFSF15) generated by differential ectodomain shedding.","date":"2010","source":"The journals of gerontology. Series A, Biological sciences and medical sciences","url":"https://pubmed.ncbi.nlm.nih.gov/20675618","citation_count":23,"is_preprint":false},{"pmid":"24846800","id":"PMC_24846800","title":"Detection rates and phenotypic spectrum of m.3243A>G in the MT-TL1 gene: a molecular diagnostic laboratory perspective.","date":"2014","source":"Mitochondrion","url":"https://pubmed.ncbi.nlm.nih.gov/24846800","citation_count":23,"is_preprint":false},{"pmid":"19760077","id":"PMC_19760077","title":"Therapeutic Potential of VEGI/TL1A in Autoimmunity and Cancer.","date":"2009","source":"Advances in experimental medicine and biology","url":"https://pubmed.ncbi.nlm.nih.gov/19760077","citation_count":22,"is_preprint":false},{"pmid":"25161149","id":"PMC_25161149","title":"Death receptor 3 mediates TNFSF15- and TNFα-induced endothelial cell apoptosis.","date":"2014","source":"The international journal of biochemistry & cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/25161149","citation_count":22,"is_preprint":false},{"pmid":"32827707","id":"PMC_32827707","title":"TNFSF15 Promotes Antimicrobial Pathways in Human Macrophages and These Are Modulated by TNFSF15 Disease-Risk Variants.","date":"2020","source":"Cellular and molecular gastroenterology and hepatology","url":"https://pubmed.ncbi.nlm.nih.gov/32827707","citation_count":22,"is_preprint":false},{"pmid":"28261213","id":"PMC_28261213","title":"Age-Dependent Association of TNFSF15/TNFSF8 Variants and Leprosy Type 1 Reaction.","date":"2017","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/28261213","citation_count":21,"is_preprint":false},{"pmid":"16517446","id":"PMC_16517446","title":"Vascular endothelial growth inhibitor (VEGI), an endogenous negative regulator of angiogenesis.","date":"2006","source":"Seminars in ophthalmology","url":"https://pubmed.ncbi.nlm.nih.gov/16517446","citation_count":20,"is_preprint":false},{"pmid":"35255540","id":"PMC_35255540","title":"The TL1A-DR3 Axis in Asthma: Membrane-Bound and Secreted TL1A Co-Determined the Development of Airway Remodeling.","date":"2022","source":"Allergy, asthma & immunology research","url":"https://pubmed.ncbi.nlm.nih.gov/35255540","citation_count":20,"is_preprint":false},{"pmid":"35359966","id":"PMC_35359966","title":"TL1A/DR3 Axis, A Key Target of TNF-a, Augments the Epithelial-Mesenchymal Transformation of Epithelial Cells in OVA-Induced Asthma.","date":"2022","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/35359966","citation_count":20,"is_preprint":false},{"pmid":"27120595","id":"PMC_27120595","title":"TNFSF15 Inhibits Blood Retinal Barrier Breakdown Induced by Diabetes.","date":"2016","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/27120595","citation_count":19,"is_preprint":false},{"pmid":"28183800","id":"PMC_28183800","title":"TNFSF15 inhibits VEGF-stimulated vascular hyperpermeability by inducing VEGFR2 dephosphorylation.","date":"2017","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/28183800","citation_count":18,"is_preprint":false},{"pmid":"26200500","id":"PMC_26200500","title":"Association of Genetic Variations in TNFSF15 With Acute Anterior Uveitis in Chinese Han.","date":"2015","source":"Investigative ophthalmology & visual science","url":"https://pubmed.ncbi.nlm.nih.gov/26200500","citation_count":18,"is_preprint":false},{"pmid":"24141405","id":"PMC_24141405","title":"Interferon-γ produced by tumor-infiltrating NK cells and CD4+ T cells downregulates TNFSF15 expression in vascular endothelial cells.","date":"2013","source":"Angiogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/24141405","citation_count":18,"is_preprint":false},{"pmid":"24783249","id":"PMC_24783249","title":"Combining TNFSF15 and ASCA IgA can be used as a predictor for the stenosis/perforating phenotype of Crohn's disease.","date":"2014","source":"Journal of gastroenterology and hepatology","url":"https://pubmed.ncbi.nlm.nih.gov/24783249","citation_count":18,"is_preprint":false},{"pmid":"22388993","id":"PMC_22388993","title":"Advancement in the research on vascular endothelial growth inhibitor (VEGI).","date":"2012","source":"Targeted oncology","url":"https://pubmed.ncbi.nlm.nih.gov/22388993","citation_count":17,"is_preprint":false},{"pmid":"32381123","id":"PMC_32381123","title":"Circulating TNF-like protein 1A (TL1A) is elevated early in rheumatoid arthritis and depends on TNF.","date":"2020","source":"Arthritis research & therapy","url":"https://pubmed.ncbi.nlm.nih.gov/32381123","citation_count":17,"is_preprint":false},{"pmid":"31176785","id":"PMC_31176785","title":"TL1A modulates the severity of colitis by promoting Th9 differentiation and IL-9 secretion.","date":"2019","source":"Life sciences","url":"https://pubmed.ncbi.nlm.nih.gov/31176785","citation_count":17,"is_preprint":false},{"pmid":"20403353","id":"PMC_20403353","title":"Functional signaling of membrane-bound TL1A induces IFN-gamma expression.","date":"2010","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/20403353","citation_count":17,"is_preprint":false},{"pmid":"34305924","id":"PMC_34305924","title":"Targeting TL1A/DR3 Signaling Offers a Therapeutic Advantage to Neutralizing IL13/IL4Rα in Muco-Secretory Fibrotic Disorders.","date":"2021","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/34305924","citation_count":16,"is_preprint":false},{"pmid":"26936681","id":"PMC_26936681","title":"Downregulation of VEGF and upregulation of TL1A expression induce HUVEC apoptosis in response to high glucose stimuli.","date":"2016","source":"Molecular medicine reports","url":"https://pubmed.ncbi.nlm.nih.gov/26936681","citation_count":16,"is_preprint":false},{"pmid":"24416448","id":"PMC_24416448","title":"TL1A induces TCR independent IL-6 and TNF-α production and growth of PLZF⁺ leukocytes.","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/24416448","citation_count":15,"is_preprint":false},{"pmid":"29335258","id":"PMC_29335258","title":"Cleavage of TL1A Differentially Regulates Its Effects on Innate and Adaptive Immune Cells.","date":"2018","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/29335258","citation_count":15,"is_preprint":false},{"pmid":"29748156","id":"PMC_29748156","title":"TL1A mediates fibroblast-like synoviocytes migration and Indian Hedgehog signaling pathway via TNFR2 in patients with rheumatoid arthritis.","date":"2018","source":"European cytokine network","url":"https://pubmed.ncbi.nlm.nih.gov/29748156","citation_count":15,"is_preprint":false},{"pmid":"30101034","id":"PMC_30101034","title":"Counterbalance: modulation of VEGF/VEGFR activities by TNFSF15.","date":"2018","source":"Signal transduction and targeted therapy","url":"https://pubmed.ncbi.nlm.nih.gov/30101034","citation_count":14,"is_preprint":false},{"pmid":"25908025","id":"PMC_25908025","title":"Secretion, blood levels and cutaneous expression of TL1A in psoriasis patients.","date":"2015","source":"APMIS : acta pathologica, microbiologica, et immunologica Scandinavica","url":"https://pubmed.ncbi.nlm.nih.gov/25908025","citation_count":14,"is_preprint":false},{"pmid":"33986858","id":"PMC_33986858","title":"Analysis of therapeutic potential of preclinical models based on DR3/TL1A pathway modulation (Review).","date":"2021","source":"Experimental and therapeutic medicine","url":"https://pubmed.ncbi.nlm.nih.gov/33986858","citation_count":14,"is_preprint":false},{"pmid":"37269079","id":"PMC_37269079","title":"TL1A promotes the postoperative cognitive dysfunction in mice through NLRP3-mediated A1 differentiation of astrocytes.","date":"2023","source":"CNS neuroscience & therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/37269079","citation_count":14,"is_preprint":false},{"pmid":"40010414","id":"PMC_40010414","title":"TL1A, a novel alarmin in airway, intestinal, and autoimmune disorders.","date":"2025","source":"The Journal of allergy and clinical immunology","url":"https://pubmed.ncbi.nlm.nih.gov/40010414","citation_count":13,"is_preprint":false},{"pmid":"30809418","id":"PMC_30809418","title":"Role of TNFSF15 in the intestinal inflammatory response.","date":"2018","source":"World journal of gastrointestinal pathophysiology","url":"https://pubmed.ncbi.nlm.nih.gov/30809418","citation_count":13,"is_preprint":false},{"pmid":"26768609","id":"PMC_26768609","title":"Evaluation of (188)Re-labeled NGR-VEGI protein for radioimaging and radiotherapy in mice bearing human fibrosarcoma HT-1080 xenografts.","date":"2016","source":"Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/26768609","citation_count":13,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":51805,"output_tokens":10932,"usd":0.159697,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":21640,"output_tokens":6425,"usd":0.134412,"stage2_stop_reason":"end_turn"},"total_usd":0.294109,"stage1_batch_id":"msgbatch_017qqVz33Ga63SCDwzb35XPb","stage2_batch_id":"msgbatch_01Scr2Ei9x4HJMiRGxwrmvLK","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2002,\n      \"finding\": \"TL1A (TNFSF15) is a ligand for DR3 (death domain-containing receptor) and decoy receptor TR6/DcR3. TL1A binding to DR3 induces NF-κB activation and apoptosis in DR3-expressing cell lines, and TR6-Fc protein antagonizes these signaling events. In T cells, TL1A acts as a costimulator that increases IL-2 responsiveness and secretion of proinflammatory cytokines.\",\n      \"method\": \"Ligand-receptor binding assays, NF-κB reporter assays, apoptosis assays, T cell costimulation assays in vitro and in vivo\",\n      \"journal\": \"Immunity\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — direct ligand-receptor identification with multiple orthogonal functional assays (NF-κB activation, apoptosis, cytokine secretion), foundational paper replicated by many subsequent studies\",\n      \"pmids\": [\"11911831\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"TL1A-DR3 interaction induces formation of a signaling complex containing TRADD, TRAF2, and RIP, and activates NF-κB and ERK, JNK, and p38 MAPK pathways. TL1A-induced NF-κB activation produces c-IAP2, which prevents DR3-mediated apoptosis in TF-1 cells. Inhibition of NF-κB or knockdown of c-IAP2 by RNA interference sensitizes cells to TL1A-induced apoptosis.\",\n      \"method\": \"Co-immunoprecipitation of signaling complex, NF-κB reporter assays, MAPK pathway inhibitors, RNA interference (siRNA knockdown of c-IAP2), apoptosis assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — reconstitution of signaling complex by Co-IP, multiple orthogonal methods (inhibitors, RNAi, reporter assays) in a single study\",\n      \"pmids\": [\"12882979\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"TL1A (VEGI/TNFSF15) is expressed predominantly in endothelial cells, encodes a type II transmembrane protein, and the secreted (soluble) form directly inhibits endothelial cell proliferation and suppresses tumor vascularization in vivo. Local gene transfer of soluble VEGI caused complete suppression of murine colon cancer growth associated with marked reduction in vascularization.\",\n      \"method\": \"cDNA cloning from HUVEC library, gene transfer/tumor model (MC-38 murine colon cancer), in vitro endothelial cell proliferation assay, histological analysis of vascularization\",\n      \"journal\": \"FASEB journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — in vitro functional assay plus in vivo tumor model with histological validation, foundational paper replicated by multiple subsequent studies\",\n      \"pmids\": [\"9872942\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"TL1A (TL1) induces apoptosis in endothelial cells via activation of stress-activated protein kinase (SAPK/JNK) and p38 MAPK pathways and caspase-3. TL1-induced apoptosis was reduced by dominant-interfering c-Jun mutant, p38 inhibitor SB203580, and caspase inhibitor ZVAD-fmk. The effect was not inhibited by soluble TNF receptors 1 or 2, indicating a distinct receptor.\",\n      \"method\": \"Endothelial cell apoptosis assays, kinase activity assays (SAPK, p38), dominant-negative mutant expression, pharmacological inhibitors, caspase substrate assays, immunocytochemistry\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — multiple orthogonal methods (dominant-negative, inhibitors, kinase assays) in a single study with rigorous controls\",\n      \"pmids\": [\"9880523\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"VEGI (TNFSF15) activates NF-κB (inducing IκBα degradation and p65 nuclear translocation) and c-Jun N-terminal kinase in myeloid cells, inhibits proliferation of multiple tumor cell lines, and activates caspase-3 leading to PARP cleavage. Its activity cannot be neutralized by anti-TNF antibodies and it does not compete with TNF binding, indicating it acts through a distinct receptor.\",\n      \"method\": \"EMSA (NF-κB activation), reporter gene assay, IκBα degradation assay, JNK kinase assay, cell proliferation assay, caspase-3/PARP cleavage assay\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — multiple orthogonal biochemical assays (EMSA, kinase assay, reporter, PARP cleavage) in a single study\",\n      \"pmids\": [\"10597252\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"VEGI-192, a new isoform of TNFSF15, systemically administered suppresses tumor growth and specifically eliminates tumor endothelial cells but not vascular smooth muscle cells, with no liver or kidney toxicity. VEGI expression in normal tissue is restricted largely to endothelial cells by immunohistochemistry.\",\n      \"method\": \"Recombinant protein production, systemic i.p./i.v./s.c. injection in Lewis lung carcinoma mouse model, histological analysis, immunohistochemistry\",\n      \"journal\": \"Clinical cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo tumor model with histological analysis of vascular cell selectivity, single lab but multiple readouts\",\n      \"pmids\": [\"16061878\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"Soluble TL1A is naturally secreted from HUVECs as a 30–32 kDa protein, and its production is significantly induced by IL-1α and TNF. IL-1 is a more potent inducer than TNF, and the induction is dose- and time-dependent.\",\n      \"method\": \"ELISA development, Western blot under reducing/non-reducing conditions, affinity purification of soluble TL1A from conditioned medium\",\n      \"journal\": \"Journal of immunological methods\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct biochemical characterization (ELISA, Western blot, affinity purification) with quantitative dose-response data, single lab\",\n      \"pmids\": [\"15847792\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"TL1A expression in human monocytes and monocyte-derived dendritic cells is specifically induced by FcγR signaling (immune complexes), correlating with surface and secreted TL1A protein. TLR agonists capable of inducing IL-6 and TNF-α do not induce surface or soluble TL1A. TL1A produced by monocytes enhances T cell IFN-γ responses.\",\n      \"method\": \"Stimulation assays with TLR agonists, IFN-γ, and immune complexes; surface expression by flow cytometry; TL1A ELISA; T cell co-culture assays\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct functional assays with defined stimuli, multiple readouts (surface expression, secretion, T cell function), single lab\",\n      \"pmids\": [\"17371957\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"DR3 expression is selectively elevated in Th17 cells, and TL1A promotes proliferation of effector Th17 cells. TL1A-deficient dendritic cells have reduced capacity to support Th17 differentiation and proliferation. In experimental autoimmune encephalomyelitis (EAE), TL1A-knockout animals show decreased clinical severity and reduced Th17 differentiation and effector function.\",\n      \"method\": \"TL1A-knockout mouse generation, EAE model, flow cytometry analysis of Th17 cells, DC co-culture differentiation assays\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic KO model with defined cellular phenotype (Th17 defect), in vivo disease model, DC functional assay; independent replication of TL1A-DR3 in Th17 biology across multiple papers\",\n      \"pmids\": [\"18411337\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Crystal structure of the human TL1A extracellular domain at 2.5 Å resolution reveals a jelly-roll fold typical of the TNF superfamily. Mutagenesis and biochemical characterization define the binding interface for DcR3 and DR3 receptors, suggesting the mode of TL1A–DcR3 interaction differs from other characterized TNF ligand/receptor complexes.\",\n      \"method\": \"X-ray crystallography (2.5 Å resolution), site-directed mutagenesis, biochemical binding assays\",\n      \"journal\": \"Biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — crystal structure with mutagenesis and biochemical validation in a single rigorous study\",\n      \"pmids\": [\"19522538\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"VEGI (TNFSF15) inhibits the differentiation of endothelial progenitor cells (EPCs) from bone marrow Sca1+ mononuclear cells, decreasing endothelial cell marker expression and capability for adhesion, migration, and capillary-like structure formation. VEGI induces apoptosis of differentiated EPCs but not early-stage EPCs; in early-stage EPCs it increases phospho-ERK and decreases phospho-Akt, while in differentiated EPCs it activates NF-κB, JNK, and caspase-3. DR3 is present only on differentiated EPCs and mediates VEGI-induced apoptosis, as shown by neutralizing anti-DR3 antibodies or recombinant DR3 extracellular domain.\",\n      \"method\": \"In vitro EPC differentiation assay, flow cytometry (EPC markers), adhesion/migration/Matrigel assays, Western blot (signaling), neutralizing antibodies against DR3\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — multiple orthogonal methods (functional assays, signaling, receptor neutralization), clearly establishes DR3 as the mediating receptor for a specific cell-stage-dependent effect\",\n      \"pmids\": [\"19329781\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Multiple bacterial species (gram-negative, gram-positive, anaerobes) induce TL1A expression in human APCs (monocytes and monocyte-derived DCs) via TLR signaling, which is inhibited by downstream blockade of p38 MAPK and NF-κB. Bacterially induced TL1A production by APCs potentiates CD4+ T-cell IFN-γ production.\",\n      \"method\": \"Bacterial stimulation assays, TL1A mRNA/protein quantification, p38 and NF-κB pathway inhibitors, T cell co-culture IFN-γ assays\",\n      \"journal\": \"European journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pathway inhibitor experiments establishing signaling requirements, multiple bacterial species tested, functional T cell readout; single lab\",\n      \"pmids\": [\"19839006\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"TNFSF15 is a downstream transcriptional target of AMPK, mediated through LITAF binding to a specific sequence in the TNFSF15 promoter region. AMPK activation by AICAR upregulates TNFSF15, and this is abrogated by shRNA or dominant-negative AMPK α1. TNFSF15 inhibits growth of prostate cancer cells and bovine aortic endothelial cells in vitro, and intratumoral injection of TNFSF15 reduces tumor size and blood vessel number in vivo.\",\n      \"method\": \"shRNA knockdown, dominant-negative AMPK mutant, promoter binding assay (LITAF-TNFSF15 promoter), cell proliferation assay, xenograft tumor model, histological analysis\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple genetic and pharmacological approaches establish AMPK–LITAF–TNFSF15 regulatory axis, single lab with both in vitro and in vivo readouts\",\n      \"pmids\": [\"21217782\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Sustained TL1A expression on DCs drives goblet cell hyperplasia in the ileum associated with elevated IL-13 levels and increased IL-13- and IL-17-producing T cells. TL1A directly stimulates Treg cell proliferation in vitro and enhances Treg turnover in vivo via DR3 signaling. TL1A also attenuates the ability of Treg cells to suppress conventional T cells, requiring DR3 signaling in either conventional or Treg cells.\",\n      \"method\": \"TL1A transgenic mice (DC-specific expression), IL-13 quantification, flow cytometry of T cell subsets, in vitro Treg proliferation assay, suppression assays\",\n      \"journal\": \"Mucosal immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — transgenic mouse model with multiple cellular readouts and in vitro mechanistic validation; single lab\",\n      \"pmids\": [\"20962771\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Two functionally distinct isoforms of TL1A are generated by differential ectodomain shedding: TL1A(L72-L251) and a novel shorter fragment TL1A(V84-L251). TL1A overexpression induces premature senescence in HUVECs and endothelial progenitor cells, and knockdown of TL1A partially reverts senescence. The novel TL1A(V84-L251) fragment induces growth arrest and apoptosis in HUVECs.\",\n      \"method\": \"Ectodomain shedding characterization, TL1A overexpression and knockdown (siRNA) in HUVECs and EPCs, senescence assays, apoptosis/growth arrest assays\",\n      \"journal\": \"The journals of gerontology. Series A, Biological sciences and medical sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct experimental identification of novel cleavage fragment with functional assays; single lab\",\n      \"pmids\": [\"20675618\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Soluble TL1A-Ig (a dimer of TL1A trimers) signals through TNFRSF25 to rapidly expand Foxp3+ Tregs in vivo (up to 30–35% of CD4+ T cells within 5 days), dependent on TCR engagement with MHC class II. TL1A-Ig-expanded Tregs express high levels of KLRG1 and CD103, are highly suppressive ex vivo, and protect against allergic lung inflammation in a mouse asthma model.\",\n      \"method\": \"TL1A-Ig fusion protein generation/characterization (SEC-MALS), in vivo Treg expansion assay, flow cytometry, MHC class II dependency experiments, asthma model (eosinophil/BAL analysis)\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — defined fusion protein with in vivo functional characterization and mechanistic (MHC dependency) validation; single lab\",\n      \"pmids\": [\"23319737\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"TNFSF15 (VEGI) inhibits EPC-supported vasculogenesis by simultaneously promoting mFlt1 (membrane VEGFR1) degradation through Akt deactivation-dependent, ubiquitin-assisted degradation, and upregulating sFlt1 (soluble VEGFR1) expression via the PKC/Src/Erk1/2 signaling pathway. TNFSF15 also promotes alternative splicing of Flt1 in favor of sFlt1 by downregulating nuclear protein Jmjd6, thereby disrupting VEGF/PlGF-induced eNOS and MAPK p38 activation and inhibiting EPC-supported vasculogenesis in vivo.\",\n      \"method\": \"In vitro EPC culture, Western blot (phosphorylation, ubiquitination), pathway inhibitors (PKC, Src, Erk1/2), Jmjd6 knockdown, in vivo Matrigel implant model, alternative splicing analysis\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — multiple orthogonal biochemical and genetic approaches with in vivo validation; mechanistically detailed single study\",\n      \"pmids\": [\"23918400\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"TNFSF15:DR3 interactions in human macrophages amplify PRR-initiated MAPK/NF-κB/PI3K signaling and cytokine secretion. Mechanism involves TACE-induced cleavage of TNFSF15 to soluble form, which then signals via TRADD/FADD/MALT-1 and caspase-8 to induce autocrine IL-1 secretion. The rs6478108 A disease-risk allele is associated with increased TNFSF15 expression and increased PRR-induced signaling and cytokines in macrophages.\",\n      \"method\": \"Human macrophage stimulation assays, pathway inhibitors (TACE, NF-κB, PI3K, MAPK), caspase-8 inhibition, ELISA, genotype-stratified analysis\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — multiple orthogonal mechanistic experiments (protease inhibitors, caspase-8, signaling inhibitors) plus genotype-function correlation in primary human cells\",\n      \"pmids\": [\"25197060\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"TL1A directly signals through DR3 on intestinal myofibroblasts to increase collagen and IL-31Ra expression. Blocking TL1A with neutralizing antibody or deletion of DR3 reduces the number of fibroblasts and myofibroblasts and reverses established murine colonic fibrosis, reducing connective tissue growth factor, TGF-β1, and IGF-1 expression.\",\n      \"method\": \"Neutralizing anti-Tl1a antibody treatment in murine colitis model, Dr3 knockout mice, primary intestinal myofibroblast culture with TL1A stimulation, collagen and cytokine quantification\",\n      \"journal\": \"Mucosal immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic (DR3 KO) and antibody blockade approaches converge on same phenotype; direct in vitro fibroblast stimulation; replicated by subsequent studies\",\n      \"pmids\": [\"24850426\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Soluble trimeric TL1A fully activates DR3-associated pro- and anti-apoptotic signaling pathways without requiring secondary oligomerization. DR3 is efficiently activated by soluble TL1A trimers (similar to TNFR1, unlike TRAIL receptors which require oligomerization). TL1A binding induces DR3 internalization, and the affinity of TL1A-DR3 interaction was measured in a cell-based system.\",\n      \"method\": \"Cell-based DR3 activation assays (apoptosis, NF-κB), comparison with oligomerized vs. non-oligomerized soluble ligand, receptor internalization assay, affinity measurement\",\n      \"journal\": \"The FEBS journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — direct mechanistic comparison of soluble vs. membrane-bound ligand activity, receptor internalization and affinity measurements; single lab\",\n      \"pmids\": [\"26509650\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"TNFSF15 suppresses VEGF production in endothelial cells by stimulating miR-29b expression through activation of the JNK–GATA3 signaling pathway. miR-29b targets the 3'-UTR of VEGF transcript. Blocking TNFSF15 activity (via DR3 siRNA or neutralizing antibody 4-3H) inhibits miR-29b and reinstates VEGF production. JNK inhibitor (SP600125) or JNK siRNA eradicates TNFSF15-induced GATA3 expression; GATA3 siRNA suppresses TNFSF15-induced miR-29b.\",\n      \"method\": \"miRNA expression assay, 3'-UTR reporter assay, siRNA knockdown (DR3, JNK, GATA3), neutralizing antibody, JNK inhibitor (SP600125), qRT-PCR, Western blot\",\n      \"journal\": \"Oncotarget\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal siRNA and inhibitor approaches defining JNK-GATA3-miR-29b pathway; single lab\",\n      \"pmids\": [\"27589684\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"TNFSF15 inhibits VEGF-induced vascular hyperpermeability in vitro and in vivo through DR3-mediated dephosphorylation of VEGFR2. Upon TNFSF15-DR3 interaction, SHP-1 (a phosphatase) becomes associated with DR3, and a ternary protein complex consisting of VEGFR2, DR3, and SHP-1 is formed, providing the structural basis for VEGFR2 dephosphorylation.\",\n      \"method\": \"In vitro vascular permeability assay, in vivo permeability model, Co-immunoprecipitation (VEGFR2–DR3–SHP-1 complex), Western blot (VEGFR2 phosphorylation), siRNA knockdown\",\n      \"journal\": \"FASEB journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — biochemical complex formation by Co-IP plus functional phosphorylation assays in vitro and in vivo; mechanistically detailed single study\",\n      \"pmids\": [\"28183800\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Membrane-bound TL1A and soluble TL1A have differential roles: membrane TL1A promotes inflammatory cytokine expression in the lung dependent on DR3 on T cells (adaptive immunity), while soluble TL1A alone is sufficient to induce intestinal type 2 inflammation independently of T cells (innate lymphoid cells). These differential activities were demonstrated using membrane-restricted TL1A-transgenic mice.\",\n      \"method\": \"Generation of membrane-restricted TL1A-transgenic mice (cleavage site mutant), comparison with soluble TL1A-expressing mice, DR3-deficient crosses, lung cytokine and intestinal pathology analysis\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic dissection using membrane-restricted transgene plus DR3-KO crosses, clearly separates membrane vs. soluble TL1A functions in defined cell populations\",\n      \"pmids\": [\"29335258\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Membrane-bound TL1A (TL1A-M) can bind DR3 through cell-cell contact and signal to induce IFN-γ secretion enhancement from IL-12/IL-18-primed CD4+ T cells. This was blocked by anti-TL1A antibody, demonstrating functional signaling capacity of the membrane-bound form.\",\n      \"method\": \"TL1A-M expression in HEK-293 cells, DR3-Fc binding assay, co-incubation with primed T cells, IFN-γ ELISA, antibody blocking\",\n      \"journal\": \"FEBS letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct cell-cell contact assay establishing membrane-bound TL1A functional signaling through DR3; single lab\",\n      \"pmids\": [\"20403353\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"TL1A directly induces proinflammatory cytokines including TNF-α from CD3+CD161+ (CD4+CD161+) T cells. Anti-TNF-α failed to block TL1A-induced cytokine production, indicating TL1A effects are independent of and upstream of TNFα.\",\n      \"method\": \"Isolation of CD4+CD161+ T cells, TL1A stimulation, cytokine ELISA, anti-TNFα antibody blocking experiments\",\n      \"journal\": \"Mucosal immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct cell stimulation with receptor-specific blocking, establishes pathway position of TL1A upstream of TNFα; single lab\",\n      \"pmids\": [\"23250276\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Plasma cells (but not B cells) express high levels of DR3 and are direct targets of TL1A. In the presence of TL1A, plasma cells survive better and produce more anti-collagen antibody. TL1A gene knockout mice show ameliorated collagen-induced arthritis with reduced pathogenic anti-collagen Ab titers.\",\n      \"method\": \"TL1A KO mouse generation, CIA model, flow cytometry (DR3 expression on B cells and plasma cells), plasma cell survival and antibody production assays\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic KO model plus direct in vitro plasma cell functional assays; single lab\",\n      \"pmids\": [\"24140642\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Autocrine/paracrine TNFSF15:DR3 interactions are required for optimal PRR-induced bacterial clearance in human macrophages. TNFSF15 induces bacterial uptake via pyruvate dehydrogenase kinase 1 and promotes intracellular bacterial clearance through reactive oxygen species, nitric oxide synthase 2, and autophagy upregulation. The TNFSF15-initiated TRAF2/RIPK1/RIP3 pathway (but not the FADD/MALT-1/caspase-8 pathway) is required for MAPK and NF-κB activation and antimicrobial pathways.\",\n      \"method\": \"Human monocyte-derived macrophage assays, flow cytometry, ELISA, gentamicin protection assay (bacterial clearance), pathway inhibitors (TRAF2, RIPK1, RIP3, FADD, caspase-8), ROS/NOS2/autophagy assays, genotype-stratified analysis of IBD risk carriers\",\n      \"journal\": \"Cellular and molecular gastroenterology and hepatology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple pathway inhibitors and complementation experiments defining mechanistic pathway in primary human cells; genotype-function correlation adds further rigor\",\n      \"pmids\": [\"32827707\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"TL1A directly signals through DR3 on lung fibroblasts and bronchial epithelial cells to induce proliferation and production of fibrotic molecules (collagen, periostin), driving airway remodeling. Neutralization of TL1A or genetic deletion of DR3 restricts peribronchial smooth muscle mass and lung collagen accumulation in allergen- and bleomycin-driven mouse models. Recombinant TL1A administered into naive mouse airways drives remodeling independently of innate lymphoid cells and adaptive immunity.\",\n      \"method\": \"Anti-TL1A antibody neutralization, DR3-KO mice, recombinant TL1A instillation in naive mice, human lung fibroblast and bronchial epithelial cell culture with TL1A stimulation, collagen/periostin quantification\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic (DR3 KO) and antibody approaches converge; direct structural cell stimulation experiments; in vivo cell-type independent model establishes direct fibroblast mechanism\",\n      \"pmids\": [\"32958689\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Direct TL1A-DR3 signaling on fibroblasts promotes intestinal fibrosis in vivo. Transfer of TL1A-overexpressing T cells into Rag-/- mice with DR3 deleted specifically on fibroblasts (Rag-/-Dr3ΔCol1a2) showed reduced intestinal fibrosis and attenuated fibroblast activation and migration compared to Rag-/- controls, despite similar inflammation. RNA-Seq of TL1A-stimulated fibroblasts identified Rho signal transduction as a major activated pathway, and inhibition of this pathway modulated TL1A-mediated fibroblast functions.\",\n      \"method\": \"Adoptive T cell transfer into Rag-/-, Rag-/-Dr3-/-, and Rag-/-Dr3ΔCol1a2 mice, collagen deposition quantification, RNA-Seq of TL1A-stimulated fibroblasts, Rho pathway inhibition\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — cell-type-specific DR3 KO (fibroblast-selective) definitively establishes direct TL1A-fibroblast signaling in vivo; RNA-Seq identifies downstream pathway; single rigorous study\",\n      \"pmids\": [\"33097818\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"DR3 mediates TNFSF15-induced endothelial cell apoptosis. siRNA-mediated knockdown of DR3 confers resistance to TNFSF15-induced apoptosis. DR3-depleted cells show increased ERK1/2 MAPK activity and upregulation of anti-apoptotic proteins c-FLIP and Bcl-2. Additionally, TNFα-induced apoptosis is also dependent on TNFSF15 upregulation stimulated by TNFα, as TNFSF15 siRNA or neutralizing antibody inhibits TNFα-induced apoptosis.\",\n      \"method\": \"siRNA knockdown of DR3 and TNFSF15, in vivo Matrigel angiogenesis assay, endothelial cell culture apoptosis assays, Western blot (ERK, c-FLIP, Bcl-2), neutralizing antibody (4-3H)\",\n      \"journal\": \"The international journal of biochemistry & cell biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple siRNA and antibody experiments in vitro and in vivo Matrigel assay; single lab\",\n      \"pmids\": [\"25161149\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"TL1A is constitutively expressed as an epithelial alarmin in alveolar epithelium at steady state in mice and humans (including airway basal cells). Upon synergistic activation by IL-33 and TL1A, lung ILC2s acquire a transient IL-9highGATA3low 'ILC9' phenotype and produce large amounts of IL-9. Large-scale proteomic analysis, lung intravital microscopy, and adoptive transfer experiments revealed that IL-9high distinguishes a multicytokine-producing ILC2 state with increased capacity to initiate IL-5-dependent allergic airway inflammation.\",\n      \"method\": \"Proteomic analyses, lung intravital microscopy, adoptive transfer of ILC9 cells, in vitro ILC2 stimulation (IL-33 + TL1A), flow cytometry, IL-9/IL-5 functional assays in mouse models\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods (proteomics, live imaging, adoptive transfer, in vitro stimulation); identifies new cellular mechanism and cell source of TL1A\",\n      \"pmids\": [\"38597952\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"The IBD-risk haplotype at TNFSF15 is associated with decreased expression of TNFSF15 by peripheral blood monocytes (at both RNA and protein levels) under various stimulation conditions, maintained after macrophage differentiation. The regulatory polymorphism controlling TNFSF15 expression was localized to the upstream regulatory region of the gene using recall-by-genotype fine-mapping. Genetically regulated TNFSF15 has functional relevance as shown by a T cell costimulation assay.\",\n      \"method\": \"Recall-by-genotype functional fine-mapping, allele-specific expression measurement, monocyte stimulation assays (RNA and protein), macrophage differentiation, T cell costimulation assay\",\n      \"journal\": \"PLoS genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — allele-specific expression fine-mapping with functional validation; defines regulatory mechanism of disease-associated variant; single study\",\n      \"pmids\": [\"30199539\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"TL1A gene haplotype B increases TL1A expression in response to FcγR stimulation in Jewish CD patients positive for OmpC antibody. CD14+ monocytes from patients homozygous for haplotype B express higher levels of TL1A, and peripheral monocytes show increased membrane TL1A expression.\",\n      \"method\": \"SNP haplotyping, monocyte isolation and FcγR stimulation, ELISA for TL1A protein, flow cytometry for membrane TL1A\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — haplotype-stratified functional assay in primary human monocytes; single lab\",\n      \"pmids\": [\"19262684\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"TL1A-mediated intestinal fibrosis and fibroblast activation are dependent on specific microbial populations. In germ-free Tl1a-transgenic mice, the pro-fibrotic and inflammatory phenotype is abrogated. Reconstitution with SPF (but not healthy human) microbiota restores intestinal collagen deposition and fibroblast activation. Candidate organisms correlating with fibrosis were identified and shown to directly impact fibroblast function in vitro.\",\n      \"method\": \"Germ-free Tl1a-transgenic mice, microbiome reconstitution by gavage (SPF vs. human donor stool), collagen deposition quantification, fibroblast migration/activation assays in vitro\",\n      \"journal\": \"Mucosal immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — germ-free genetic model with microbiome reconstitution and in vitro fibroblast functional assays; single lab\",\n      \"pmids\": [\"29988118\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"TL1A promotes EMT (epithelial-mesenchymal transition) in intestinal epithelial cells via the TGF-β1/Smad3 pathway, with increased expression of IL-13 and EMT transcription factors ZEB1 and Snail1. TL1A-induced EMT is inhibited by anti-TL1A antibody or BMP-7 in vitro.\",\n      \"method\": \"IBD patient tissue analysis, TL1A transgenic mouse DSS-colitis model, HT-29 cell stimulation with TL1A/anti-TL1A/BMP-7, Western blot and qPCR for EMT markers (E-cadherin, FSP1, α-SMA), pathway analysis (TGF-β1/Smad3)\",\n      \"journal\": \"Mediators of inflammation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vitro and in vivo models with antibody blockade establishing TGF-β1/Smad3 pathway involvement; single lab\",\n      \"pmids\": [\"34257516\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"TL1A mediates RA fibroblast-like synoviocyte (FLS) migration and activates Indian Hedgehog (IHH) signaling, including upregulation of IHH and its receptors PTCH1 and PTCH2. This effect is mediated through TNFR2, and blocking TL1A with TNFR2 antagonist reduces IHH expression and FLS migration.\",\n      \"method\": \"RA-FLS isolation from patients, TL1A stimulation, TNFR2 antagonist blocking, qRT-PCR and Western blot (IHH, PTCH1/2), FLS migration assay\",\n      \"journal\": \"European cytokine network\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single lab, single cell type from patients, mechanistic pathway (TNFR2 mediation of IHH) based primarily on antagonist blocking without genetic validation\",\n      \"pmids\": [\"29748156\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Chicken TL1A (ChTL1A) binds to TNFR2 and decoy receptor 3 (DcR3) and decreases the viability of CHO-K1 cells transfected with chicken TNFR2 or DcR3. ChTL1A acts as a proinflammatory cytokine in chickens, and anti-ChTL1A antibody prevents LPS-induced increases in plasma nitrite/nitrate and acute phase proteins.\",\n      \"method\": \"CHO-K1 transfection with chicken TNFR2/DcR3, cell viability assay, LPS injection in vivo, acute phase protein measurement, anti-ChTL1A antibody neutralization\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — chicken ortholog study; receptor binding via cell viability assay (indirect), single lab, limited mechanistic depth\",\n      \"pmids\": [\"18523299\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"TNFSF15 (TL1A/VEGI) is a TNF superfamily type II transmembrane cytokine predominantly produced by vascular endothelial cells and APCs that exists in membrane-bound and soluble trimeric forms (generated by metalloprotease-mediated ectodomain shedding); it signals principally through its cognate receptor DR3 (TNFRSF25), recruiting a complex containing TRADD, TRAF2, and RIP to activate NF-κB, JNK, p38 MAPK, ERK, and PI3K/Akt pathways, while also signaling through caspase-8/FADD/MALT-1 for cytokine secretion and TRAF2/RIPK1/RIP3 for antimicrobial functions; on immune cells it acts as a potent T cell (Th1, Th17, Th9) costimulator and Treg expander/modulator via DR3, while on endothelial cells and progenitor cells it inhibits proliferation, induces apoptosis via caspase-3, and suppresses vasculogenesis by simultaneously degrading membrane VEGFR1 and upregulating soluble VEGFR1, and inhibiting VEGF-induced VEGFR2 phosphorylation through a DR3–SHP-1–VEGFR2 ternary complex; membrane TL1A preferentially activates adaptive T cell responses while soluble TL1A drives innate ILC2 responses; TL1A directly signals on fibroblasts via DR3-activated Rho signaling to promote intestinal and pulmonary fibrosis; and constitutive epithelial TL1A expression qualifies it as an alarmin that cooperates with IL-33 to activate ILC2s toward an IL-9-producing state.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"TNFSF15 (TL1A/VEGI) is a TNF-superfamily type II transmembrane cytokine that operates at the interface of immune costimulation and vascular biology, signaling principally through the death-domain receptor DR3 (TNFRSF25) and being antagonized by the decoy receptor TR6/DcR3 [#0, #9]. Engagement of DR3 nucleates a TRADD–TRAF2–RIP signaling complex that activates NF-\\u03baB, ERK, JNK and p38 MAPK, with NF-\\u03baB-driven c-IAP2 setting the threshold between survival and apoptosis [#1]. Soluble trimeric TL1A, generated by metalloprotease/TACE-mediated ectodomain shedding, fully activates DR3 without requiring secondary oligomerization and triggers receptor internalization [#19, #6, #17]. On immune cells TL1A is a potent T cell costimulator: it increases IL-2 responsiveness and proinflammatory cytokine secretion [#0], drives Th17 proliferation and effector function in autoimmune disease [#8], expands and modulates Foxp3+ regulatory T cells through DR3 [#13, #15], and acts upstream of TNF\\u03b1 to elicit cytokine production from effector T cells [#24]. In macrophages TNFSF15:DR3 amplifies pattern-recognition-receptor signaling, using a FADD/MALT-1/caspase-8 branch for autocrine IL-1 secretion and a distinct TRAF2/RIPK1/RIP3 branch to drive ROS-, NOS2- and autophagy-dependent antimicrobial clearance [#17, #26]. TL1A expression is induced in antigen-presenting cells by Fc\\u03b3R engagement, bacteria and TLR signaling, while alveolar and airway epithelium express it constitutively as an alarmin that cooperates with IL-33 to push ILC2s into an IL-9-high state initiating allergic airway inflammation [#7, #11, #30]. In the vasculature TL1A inhibits endothelial cell and endothelial progenitor proliferation, induces caspase-3-dependent apoptosis, and suppresses tumor vascularization and vasculogenesis—the latter by degrading membrane VEGFR1 while upregulating soluble VEGFR1, suppressing VEGF via a JNK–GATA3–miR-29b axis, and assembling a DR3–SHP-1–VEGFR2 complex that dephosphorylates VEGFR2 [#2, #3, #16, #20, #21]. Membrane-bound and soluble TL1A are functionally divergent—membrane TL1A drives adaptive T cell responses whereas soluble TL1A drives innate type 2 inflammation [#22]—and direct DR3 signaling on fibroblasts via Rho signaling promotes intestinal and pulmonary fibrosis [#28, #18, #27]. Disease-associated TNFSF15 haplotypes alter its expression and PRR-induced signaling, linking the gene to inflammatory bowel disease [#17, #31, #32].\",\n  \"teleology\": [\n    {\n      \"year\": 1999,\n      \"claim\": \"Establishing that the endothelium-restricted cytokine VEGI/TL1A is an endogenous angiogenesis suppressor answered whether a TNF-family ligand could act on the vasculature itself rather than on immune cells.\",\n      \"evidence\": \"cDNA cloning from HUVEC, endothelial proliferation assays, and gene transfer in a murine colon cancer model with histological vascularization analysis\",\n      \"pmids\": [\"9872942\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Receptor not yet identified at this stage\", \"Mechanism of growth inhibition undefined\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Demonstrating TL1A-induced endothelial and tumor-cell apoptosis through SAPK/JNK, p38 and caspase-3, not neutralized by soluble TNF receptors or anti-TNF antibodies, established that TL1A acts via a distinct receptor from TNF.\",\n      \"evidence\": \"Endothelial/myeloid apoptosis assays, kinase assays, dominant-negative c-Jun, pharmacological inhibitors, EMSA and PARP cleavage\",\n      \"pmids\": [\"9880523\", \"10597252\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Receptor identity unresolved\", \"Relationship between proapoptotic and NF-\\u03baB outputs not defined\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Identifying DR3 as the signaling receptor and TR6/DcR3 as the decoy receptor, together with T cell costimulatory activity, unified the vascular and immune activities under a single ligand-receptor system.\",\n      \"evidence\": \"Ligand-receptor binding, NF-\\u03baB reporter and apoptosis assays, and T cell costimulation assays in vitro and in vivo\",\n      \"pmids\": [\"11911831\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Downstream adaptor complex not yet mapped\", \"Cell-type basis for apoptosis vs. costimulation outcome unclear\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Defining the TRADD–TRAF2–RIP complex and the NF-\\u03baB/c-IAP2 survival circuit explained how DR3 partitions between proinflammatory signaling and apoptosis.\",\n      \"evidence\": \"Co-immunoprecipitation of the signaling complex, MAPK inhibitors, c-IAP2 RNAi, and apoptosis assays in TF-1 cells\",\n      \"pmids\": [\"12882979\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Stoichiometry of the complex not resolved\", \"Cell-type determinants of the survival/death balance unaddressed\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Characterizing soluble TL1A as a 30\\u201332 kDa secreted product inducible by IL-1 and TNF, and an isoform (VEGI-192) with vascular-selective antitumor activity, established cytokine-regulated production and clinical anti-angiogenic potential.\",\n      \"evidence\": \"ELISA, Western blot, affinity purification from HUVEC medium; recombinant protein systemic delivery in Lewis lung carcinoma\",\n      \"pmids\": [\"15847792\", \"16061878\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Protease responsible for shedding not identified here\", \"Mechanism of vascular-cell selectivity unexplained\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"The crystal structure of the TL1A ectodomain and definition of the DR3/DcR3 binding interface provided the structural basis for receptor engagement within the TNF superfamily.\",\n      \"evidence\": \"X-ray crystallography at 2.5 \\u00c5 with site-directed mutagenesis and binding assays\",\n      \"pmids\": [\"19522538\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No co-structure with DR3 or DcR3\", \"Conformational basis for signaling not addressed\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Showing that bacteria and Fc\\u03b3R/TLR signaling induce TL1A in APCs to enhance T cell IFN-\\u03b3, and that VEGI blocks endothelial progenitor differentiation via DR3, extended TL1A function into both innate-adaptive crosstalk and progenitor-cell vasculogenesis.\",\n      \"evidence\": \"Bacterial/TLR stimulation with p38 and NF-\\u03baB inhibitors and T cell co-culture; in vitro EPC differentiation with stage-dependent signaling and anti-DR3 neutralization\",\n      \"pmids\": [\"19839006\", \"19329781\", \"17371957\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Stage-specific receptor regulation not mechanistically explained\", \"In vivo relevance of EPC effects limited\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Genetic TL1A knockout linking DR3-high Th17 cells to autoimmune disease severity established TL1A as a driver of pathogenic effector T cell responses.\",\n      \"evidence\": \"TL1A-KO mice in EAE, flow cytometry of Th17 cells, DC co-culture differentiation assays\",\n      \"pmids\": [\"18411337\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"DR3-proximal signaling in Th17 cells not dissected\", \"Contribution of other T cell subsets not resolved here\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Transgenic and membrane-form studies revealed TL1A both expands/modulates Tregs and signals through cell-cell contact, showing the cytokine tunes regulatory as well as effector arms of immunity.\",\n      \"evidence\": \"DC-specific TL1A transgenic mice with Treg proliferation/suppression assays; membrane TL1A expression in HEK-293 with DR3-Fc binding and T cell IFN-\\u03b3 readout\",\n      \"pmids\": [\"20962771\", \"20403353\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Molecular basis of Treg suppression attenuation unclear\", \"Balance of effector vs. regulatory outcomes context-dependent\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Identifying the AMPK–LITAF promoter axis defined a transcriptional control mechanism for TNFSF15 connecting metabolic signaling to its anti-angiogenic output.\",\n      \"evidence\": \"shRNA and dominant-negative AMPK, LITAF–promoter binding assay, proliferation assays, and xenograft model\",\n      \"pmids\": [\"21217782\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Physiological triggers of AMPK-driven TNFSF15 induction unclear\", \"Generality across cell types not established\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Dissecting ectodomain-shedding isoforms, Treg-expanding TL1A-Ig, and direct effects on plasma cells and effector T cells refined how distinct TL1A forms produce divergent immune and senescence outcomes.\",\n      \"evidence\": \"Shedding fragment characterization and senescence assays in HUVECs/EPCs; TL1A-Ig SEC-MALS and in vivo Treg expansion; plasma cell survival and CIA model; CD4+CD161+ T cell stimulation\",\n      \"pmids\": [\"20675618\", \"23319737\", \"24140642\", \"23250276\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Protease specificities for each fragment incompletely defined\", \"Mechanism distinguishing trimer vs. oligomer outputs not yet established\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Mechanistic studies in macrophages, fibroblasts and endothelium established that DR3 signaling outputs branch into distinct adaptor pathways and direct stromal effects, including a definitive fibroblast-driven fibrosis mechanism.\",\n      \"evidence\": \"Macrophage signaling with TACE/caspase-8/PI3K inhibitors and genotype stratification; DR3-KO and anti-TL1A in colonic fibrosis with primary myofibroblast stimulation; DR3/TNFSF15 siRNA in endothelial apoptosis\",\n      \"pmids\": [\"25197060\", \"24850426\", \"25161149\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Switch determining FADD/caspase-8 vs. other branches not fully defined\", \"Fibroblast DR3-proximal signaling not yet mapped at this stage\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Defining the VEGFR1 axis showed TNFSF15 suppresses vasculogenesis by degrading membrane VEGFR1 and upregulating soluble VEGFR1 through Akt/PKC/Src/Erk and Jmjd6-dependent splicing.\",\n      \"evidence\": \"Endothelial progenitor culture, ubiquitination and phosphorylation Western blots, pathway inhibitors, Jmjd6 knockdown, and in vivo Matrigel model\",\n      \"pmids\": [\"23918400\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"E3 ligase for membrane VEGFR1 degradation unidentified\", \"Coordination of degradation and splicing programs unclear\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Identifying the JNK–GATA3–miR-29b cascade and the DR3–SHP-1–VEGFR2 ternary complex established direct molecular routes by which TNFSF15 suppresses VEGF production and VEGFR2 signaling.\",\n      \"evidence\": \"miR-29b 3'-UTR reporter, DR3/JNK/GATA3 siRNA, JNK inhibitor; Co-IP of VEGFR2–DR3–SHP-1 and permeability assays in vitro and in vivo\",\n      \"pmids\": [\"27589684\", \"28183800\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"How DR3 recruits SHP-1 mechanistically undefined\", \"Interplay between VEGF suppression and VEGFR2 dephosphorylation not integrated\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Genetic separation of membrane-bound versus soluble TL1A established that the two forms drive adaptive (T cell) versus innate (ILC) inflammation respectively, resolving long-standing functional ambiguity.\",\n      \"evidence\": \"Membrane-restricted (cleavage-site mutant) TL1A transgenic mice crossed to DR3-deficient lines, with lung and intestinal pathology readouts\",\n      \"pmids\": [\"29335258\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular basis for differential cellular targeting unexplained\", \"Regulation of shedding in vivo unclear\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Defining IBD-risk haplotype effects on TNFSF15 expression and microbiota-dependent and EMT-driven fibrosis pathways connected genetic risk, microbial signals, and stromal pathology mechanistically.\",\n      \"evidence\": \"Recall-by-genotype fine-mapping and allele-specific expression; germ-free TL1A-transgenic mice with microbiome reconstitution; TGF-\\u03b21/Smad3 EMT analysis; Fc\\u03b3R-stimulated monocyte haplotype assays\",\n      \"pmids\": [\"30199539\", \"29988118\", \"34257516\", \"19262684\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Causal regulatory variant mechanism incompletely defined\", \"Specific microbial inducers not conclusively identified\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Defining direct DR3 signaling on fibroblasts and bronchial epithelium via Rho signaling, and macrophage antimicrobial pathways via TRAF2/RIPK1/RIP3, established TL1A as a direct driver of fibrosis and innate host defense distinct from its T cell roles.\",\n      \"evidence\": \"Fibroblast-selective DR3 deletion with adoptive T cell transfer and RNA-Seq; DR3-KO and recombinant TL1A airway models; macrophage gentamicin protection assays with TRAF2/RIPK1/RIP3 and caspase-8 inhibitors\",\n      \"pmids\": [\"33097818\", \"32958689\", \"32827707\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Rho effectors downstream of DR3 in fibroblasts not pinpointed\", \"Switch between antimicrobial and proapoptotic adaptor branches not defined\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Identifying constitutive epithelial TL1A as an alarmin cooperating with IL-33 to generate an IL-9-high ILC2 state established a tissue-resident innate mechanism for initiating allergic airway inflammation.\",\n      \"evidence\": \"Proteomics, lung intravital microscopy, adoptive transfer of ILC9 cells, and in vitro IL-33+TL1A ILC2 stimulation in mouse models\",\n      \"pmids\": [\"38597952\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Receptor/signaling integration of IL-33 and TL1A in ILC2s not resolved\", \"Human relevance of the ILC9 state not established\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How the same DR3 engagement is routed to opposing fates—survival versus apoptosis, antimicrobial versus proapoptotic adaptor branches, and adaptive versus innate effector programs—remains the central unresolved mechanistic question.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No unified model of context-dependent DR3 output selection\", \"Determinants of adaptor branch choice (FADD/caspase-8 vs. TRAF2/RIPK1/RIP3) undefined\", \"No co-structure of TL1A–DR3 signaling complex\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0048018\", \"supporting_discovery_ids\": [0, 9, 19]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [0, 1, 21]},\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [0, 1, 23]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [22, 23, 14]},\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [2, 6, 14]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [0, 1, 21]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [8, 13, 26]},\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [1, 3, 10]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"TNFRSF25\", \"TNFRSF6B\", \"TNFRSF1B\", \"TRADD\", \"TRAF2\", \"RIPK1\", \"SHP-1\", \"VEGFR2\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":9,"faith_total":9,"faith_pct":100.0}}